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 ABSTRACT 
 Glaucoma is a family of neurodegenerative diseases of the eye which results 
in retinal ganglion cell (RGC) death, optic nerve atrophy, and eventual blindness if 
left untreated.  A risk factor typically associated with glaucoma is elevated intraocular 
pressure (IOP), which most treatments are currently designed to lower.  While 
beneficial in most patients, these therapies do not provide neuroprotection to retinal 
ganglion cells.  The studies included in this dissertation present a potential 
alternative treatment for glaucoma, which provides neuroprotection to RGCs in a 
rodent model of glaucoma. 
 In these studies mesenchymal stem cells (MSCs) were used as cellular 
vehicles to deliver neuroprotective substances to compromised retinas.  Lentiviral 
vectors were used to engineer MSCs to secrete the neuroprotective protein brain-
derived neurotrophic factor (BDNF, BDNF-MSCs).  An additional line of control 
MSCs was engineered to produce green fluorescent protein (GFP, GFP-MSCs).  We 
examined the neuroprotective capacity of BDNF-MSCs using in vitro, and in vivo 
models of glaucoma, as compared to GFP-MSCs.  
 A transformed line of retinal ganglion cells, the RGC-5s, were used to model 
glaucoma in vitro following differentiation with the general kinase inhibitor 
staurosporine.  We have demonstrated a significant loss of RGC-5s following 
treatment with cellular stressors that have been implicated in RGC death in 
glaucoma, glutamate and hydrogen peroxide (H2O2), as compared to vehicle treated 
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controls.  This cell loss can be attenuated when RGC-5s are cultured in the 
presence BDNF-MSCs, but not GFP-MSCs.   
 The neuroprotective capacity of BDNF-MSCs was also examined in vivo.  
Engineered MSCs were transplanted into the rat model of chronic ocular 
hypertension (COH).  It was revealed that BDNF-MSCs, but not GFP-MSCs, were 
able to preserve retinal function and architecture, including neuroprotection of RGCs, 
following transplant.   
 These studies are the first to describe protection of retinal architecture and 
function in a model of glaucoma using MSCs to deliver a neuroprotective protein.  
Additionally, these studies pave the way toward developing treatments for human 
glaucoma that are compatible with existing treatments.   
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CHAPTER 1: GENERAL INTRODUCTION 
 
Introduction 
  Glaucoma is a family of diseases that causes irreversible blindness in 
affected patients, and is the second leading cause of blindness in the developed 
world.  A risk factor typically associated with glaucoma is increased intraocular 
pressure, which most current therapies focus on lowering.  These therapies, 
however, do not provide neuroprotection to compromised RGCs, the principal cell 
type affected in glaucoma.  In these series of experiments we use a novel cellular 
vehicle to deliver a neuroprotective protein to the retina in a rat model of glaucoma. 
The central hypothesis of this work is that mesenchymal stem cells can be 
used as cellular vehicles to deliver brain-derived neurotrophic factor to the 
retina in order to preserve retinal architecture and function in a rat model of 
glaucoma.   
A set of specific aims were generated to test this hypothesis 
 Specific Aim I: Engineer mesenchymal stem cells ex vivo to produce and 
secrete bioactive brain-derived neurotrophic factor.  
 Specific Aim II: Examine stem cell based neuroprotective strategies, in vitro, 
using a transformed retinal ganglion cell line.   
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 Specific Aim III: Use the chronic ocular hypertension model of glaucoma to 
examine the neuroprotective effect of BDNF secreting MSCs, in vivo, with regards to 
retinal architecture and function. 
Dissertation Organization 
 This dissertation is organized in the alternative format, which includes two 
manuscripts prepared for submission.  Each manuscript is a separate dissertation 
chapter.   
1. Harper MM, Adamson L, Blits B, Bunge MB, Grozdanic SD, Sakaguchi 
DS.  Brain-derived neurotrophic factor released from engineered 
mesenchymal stem cells attenuates glutamate and hydrogen peroxide 
mediated death of staurosporine differentiated RGC-5s.  Prepared for 
submission to Investigative Ophthalmology and Visual Sciences 
2. Harper MM, Grozdanic SD, Blits B, Zamzow D, Buss J, Kuehn MH, Kwon 
YH, Reger RL, Prockop DJ, Bunge MB, Kardon RH, Sakaguchi DS.  
Preservation of visual function after intraocular transplantation of BDNF 
secreting mesenchymal stem cells in glaucomatous rat eyes.  Prepared for 
submission to The Proceedings of the National Academy of Sciences.   
In addition to these two chapters, an introductory chapter containing a general 
introduction and literature review is present.  The final chapter of this dissertation 
contains general conclusions, and recommendations for future research with regards 
to this project.  
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Literature Review 
Overview 
Neurodegenerative diseases of the central nervous system (CNS) are of 
particular importance to study, as the mammalian CNS lacks regenerative capacity.  
There are many neurodegenerative diseases of the eye that lead to progressive loss 
of vision and eventual blindness.  The most prominent blinding diseases in 
developed societies according to the National Eye Institute are, in order of incidence; 
age-related macular degeneration, which principally affects cone photoreceptors1, 
glaucoma, which initially affects retinal ganglion cells (RGCs)2, diabetic retinopathy 
leading to retinal degeneration, and retinitis pigmentosa, which principally affects rod 
photoreceptors3.  The genetic components of these diseases are extremely complex, 
as in the case of retinitis pigmentosa where over 45 genes are known to be involved 
in the disease3, or for the most part unknown, as is the case with glaucoma4.   
Developing long-term, minimally invasive neuroprotective treatments to treat 
these diseases is essential to preserve retinal function in affected eyes.  The results 
presented within this dissertation focus on developing neuroprotective strategies to 
attenuate RGC loss, and preserve visual function in a rodent model of glaucoma.  
The treatment strategies proposed here have the potential to be used in human 
clinical treatments for glaucoma.  Not only are these strategies potentially useful for 
the treatment of glaucoma, they have the potential to be used in the treatment of 
other neurodegenerative diseases in order to deliver neuroprotective proteins to 
affected tissues. 
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Figure 1. Anatomical 
structures of the eye 
The Mammalian Neural Retina 
Investigations that seek to understand 
the pathophysiology of blinding diseases, as 
well as design potential treatments to prevent 
vision loss, predominately utilize the 
mammalian neural retina.  The neural retina is 
the light sensing tissue located in the posterior 
portion of the eye, and is part of the CNS5 (Fig. 
1 B).  The retina develops from the neural 
ectoderm, and is formed by optic vesicle 
evaginations from the diencephalon5.  Retinal 
development is highly regulated, with specific 
cell classes born at defined developmental 
timepoints6.  This development is a prolonged 
process that begins in utero, and is not 
completed until well after birth.  Although 
species variations exist, development of 
different cell types generally adheres to the 
same general 
pattern.  Retinal 
ganglion cells are born first, followed by cones, amacrine cells, and horizontal cells7.  
Rod photoreceptors, the largest population of cells in the retina, are born next and 
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continue until well after birth.  Finally, bipolar cells, followed by Muller glia are born 
last7.          
The mature neural retina is a highly defined laminar structure consisting of 
three cellular layers containing five classes of neurons, and two synaptic layers 
where interactions of these neurons occur8 (Fig. 1 C).  In addition to neuronal cells, 
there are two types of glial cells present in the retina; the Müller glia which are 
radially oriented in the retina, and astrocytes, which are found adjacent to the inner 
limiting membrane (ILM).  The retina is bordered by the outer limiting membrane 
(OLM) on the posterior side, and the ILM on the anterior side.  Rod and cone 
photoreceptor cell bodies make up the outer nuclear layer (ONL), the outermost, or 
posterior cellular portion of the retina.  Anterior to the ONL lies the outer plexiform 
layer (OPL), where synaptic interactions occur with cells of the inner nuclear layer 
(INL).  INL neurons that make synaptic connections in the OPL include bipolar cells 
and horizontal cells.  These inner retinal neurons transmit information to the inner 
plexiform layer (IPL), where they make synaptic connections with RGCs from the 
ganglion cell layer (GCL).  Additionally, amacrine cells of the inner nuclear layer 
mediate lateral synaptic interactions of RGCs and their synaptic partners in the IPL.  
Finally, axons of RGCs form the nerve fiber layer.  These axons form the optic 
nerve, which transmits visual field information to the brain. 
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Glaucoma 
Glaucoma is a family of ocular neuropathies that lead to RGC death, optic 
nerve degeneration, and subsequent blindness if left untreated2.  Glaucoma 
accounts for a significant portion of all blinding diseases, and it is projected that 
there will be 61 million cases of glaucoma worldwide by 2010, with 8.5 million of 
these people becoming bilaterally blind9.  Glaucoma is predicted to increase in 
frequency, with 80 million people worldwide anticipated to be affected by the year 
20209.  Aside from severely diminishing the quality of life for individuals stricken with 
this disease, glaucoma-related patient care creates an enormous economic burden 
on an already taxed healthcare system.  In the United States alone, 2.5 million cases 
of open angle glaucoma require more than 7 million office visits annually, costing in 
excess of 1.5 billion dollars10, 11.  As the population ages in the United States, it will 
become imperative to find ways to effectively and economically treat this disease 
over an extended time course to reduce the economic and patient care burden on 
the health care system.   
  Many patients begin to see side effects of glaucoma late in life, after having 
the disease for many years.  This is due to the fact that progression of the disease is 
typically painless, and many individuals are not aware they have the disease until a 
large portion of peripheral vision is lost.  In fact, the visual defects in the initial stages 
of glaucoma are so subtle that it is estimated 50% of individuals with glaucoma are 
unaware of the presence of the disease12.  It is unknown what the genetic 
component of glaucoma is, but preliminary evidence suggests it is multi-factorial, 
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with at least 22 genes being linked to some aspect of glaucoma13.  However, only a 
few genes are known in which mutations will result directly in a glaucomatous 
phenotype, such as mutant myocilin and optineurin14, 15, which are expressed in the 
trabecular meshwork, non-pigmented ciliary epithelium, ciliary body, and neural 
retina14, 15.  Additionally, two genes have been identified as being essential for the 
development of pigmentary glaucoma.  Atrophy of the iris, and pigment dispersion 
into the trabecular meshwork are due to a recessive tyrp1 gene, and a mutation in 
Gpnmb, respectively16.  Several subtypes of glaucoma exist, each with distinct 
characteristics.  We will discuss a few of the most prominent here, but focus most of 
our discussion on primary open-angle glaucoma (POAG) and its laboratory models.  
It should be noted that developing treatment strategies for one type of glaucoma 
does not rule out its use in other subtypes, as the end result in all variants of this 
disease is RGC death and a decrease in visual function.    
  In order to understand glaucoma it is essential to understand the risk factors 
and how they relate to the disease.  Increased intraocular pressure (IOP) due to 
poor aqueous humor (AH) drainage from the eye is one of the most monitored risk 
factors for the development of glaucoma, however, it is unclear what causes the 
change that leads to the increase in IOP.  Aqueous humor is located in the anterior 
segment of the eye13, and is important for correct eye function, as it supplies 
nutrients to the iris and cornea, eliminates waste, and supplies the eye with ascorbic 
acid to scavenge free radicals17 (Fig. 1 A).  Additionally, AH of the anterior chamber 
helps to maintain curvature of the cornea, which is essential for correct vision.  
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Aqueous humor is formed by the ciliary epithelium in the posterior chamber of the 
eye by the active transport of mainly NaCl from the stroma into the posterior 
chamber.  This transport is then followed by a passive diffusion of water down its 
osmotic gradient into the posterior chamber to complete the production of AH17, 18.  
After formation, AH flows through the iris and into the anterior chamber (Fig. 1 A).  
The flow of AH into the anterior chamber is continuous, therefore, it must exit the eye 
via the trabecular meshwork and uveoscleral drainage pathways to prevent an 
increase in intraocular pressure17, 19, 20.  However, if the drainage angles of the eye 
are compromised an increase in intraocular pressure occurs, which highly correlates 
with the development of glaucomatous optic neuropathies13, 21.  Recent studies have 
demonstrated morphological changes in the outflow pathways of the eye as age 
increases, with a concomitant decrease in trabecular meshwork epithelial cells, 
which leads to decreased outflow capacity of the trabecular and uveoscleral outflow 
pathways22.  A decrease in AH production is also noted as age decreases, therefore, 
the development of glaucoma later in life can easily be explained if AH production 
remains constant, or outflow capacities are dramatically decreased.  We will discuss 
the most prominent therapies currently available to patients with glaucoma, and how 
they relate to AH production and outflow.  
Most current treatments of glaucoma function by inhibiting AH production or 
increasing its outflow from the eye, not on providing neuroprotective substances in 
order to prevent retinal cell death23.  The therapies currently available to patients are 
a combination of several medical treatments and surgical procedures.  A few of the 
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widely used medical treatments include alpha-adrenergic agonists and beta-
adrenergic antagonists which vasoconstrict the ciliary body; parasympathomimetics 
and carbonic anhydrase inhibitors, which suppress the formation of aqueous humor; 
and prostaglandin analogs, which increases outflow of the aqueous humor from the 
eye13, 24.  Surgical procedures currently used to slow the progression of glaucoma 
include: laser trabeculeoplasty, which burns the trabecular meshwork to create 
greater AH outflow; laser iridotomy, which creates a hole in the iris to alleviate 
pupillary blocks; and filtration and shunt surgeries, which divert AH to alternative 
locations within the eye to collect, prior to returning to the venous system13.  While 
these treatments are useful in lowering IOP, which serves to slow the progression of 
glaucoma, none focuses directly on preserving RGCs from apoptosis.  If glaucoma is 
not detected and managed immediately in patients, there is the potential that 
secondary degeneration of RGCs may begin to occur, which would not be alleviated 
by reduction of IOP.  Additionally, if patients do not respond to treatment immediately 
and are switched between many drugs, the degeneration of RGCs proceeds 
unimpeded.  For this reason we propose a neuroprotective therapy that is capable of 
working synergistically with already proven treatments for glaucoma.        
 Glaucoma refers to a family of diseases with similar pathologies, and is often 
difficult to detect because of the limitations on readily identifiable and quantifiable 
risk factors, as well as the asymptomatic onset of the disease.  It is not until 
significant neurodegeneration has occurred that visual field impairments are obvious.  
Here, we will discuss the most prominent forms of glaucoma.  While the 
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characteristics of these forms of glaucoma are different, physicians use increased 
IOP as a risk factor for each subtype25.  Finally, while our studies use models of 
primary open-angle glaucoma (POAG), the neuroprotective treatments proposed in 
this dissertation have the potential to be used in all forms of glaucoma.  
Primary open-angle glaucoma is clinically defined as damage to the optic 
nerve that is not caused by other ocular injury, or acute closure of the drainage 
angle26.  As previously discussed, the decrease in outflow of the trabecular and 
uveoscleral pathways is due to morphological changes in the trabecular meshwork, 
coupled with increased  extracellular matrix deposition in this region22.  The hallmark 
features of POAG include morphological changes in the optic nerve head including 
enlargement of the optic cup resulting in deceased optic cup: optic disk ratios; and 
RGC death resulting in optic nerve damage.  POAG is typically accompanied by an 
increase in IOP, although increased IOP is not a requirement for the development of 
glaucoma10, 12, 26, 27.  The degeneration of RGCs leading to atrophy of the optic nerve 
is associated with a decrease in visual function beginning in peripheral visual field, 
which eventually progresses to include the central visual field, and ultimately leads to 
blindness if left untreated2.  It should be noted that the apoptosis of RGCs induces a 
secondary degeneration and apoptosis of adjacent ganglion cells that exacerbates 
the rate of vision loss28.  We hypothesize that even if glaucoma is not detected until a 
very late stage, strategies designed to attenuate RGC death in POAG have the 
potential to halt the loss of vision due to secondary neurodegeneration, and preserve 
remaining visual function.  
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Other forms of glaucoma include primary angle closure glaucoma (ACG), in 
which optic nerve damage results from acute obstruction of the drainage angles and 
trabecular meshwork, usually caused by an ocular injury26, 29.  Pigmentary glaucoma 
occurs when pigment breaks off of the iris and causes obstruction of aqueous humor 
drainage from the eye, resulting in increased IOP12, 16.  Finally, glaucoma with a 
secondary ocular pathology is caused by a secondary trauma to the eye that results 
in increased IOP, which leads to optic nerve damage.  Typically, secondary 
glaucoma involves neovascularization, uveitis, trauma to the eye, or damage to the 
lens26.   
While the genetic cause of POAG is unknown, it is theorized that a general 
sequence of events occurs in glaucomatous eyes that leads to degeneration of 
retinal ganglion cells.  An initial morphological change to the lamina cribrosa and 
glial cells of the optic nerve head area damages RGC axons, and reduces 
axoplasmic flow21.  The initial onset of degeneration may be compounded by a 
decreased outflow of AH from the anterior chamber, due to damage or dysfunction to 
the trabecular meshwork, which increases IOP.  RGC axonal damage results in a 
decreased retrograde transport of pro-survival signals to the soma, resulting in 
subsequent degeneration30, 31.  At this point it is hypothesized that many factors 
contribute to RGC degeneration, including: oxidative stress32, glutamate 
excitotoxicity33 mediated by RGCs undergoing apoptosis, involvement of the immune 
system including complement34, TNFα and TNFα receptors35, 36, and loss of 
retrograde trophic support30.  Finally, glial scarring of the neural retina and optic 
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nerves replaces lost neuronal cells and their axons21.  Developing a minimally 
invasive neuroprotective therapy is essential for attenuating RGC death for all types 
of glaucoma. 
Animal Models of Glaucoma  
 Generating reproducible models that recapitulate the pathophysiology of 
human glaucoma was paramount to elucidating many processes involved in RGC 
death.  Several mammalian models of glaucoma, especially in rodents, elevate the 
IOP of the eye in some manner, as ocular hypertension is the most quantifiable 
clinical risk factor for predicting the development of glaucoma in patients25.  Acute 
elevation of intraocular pressure (AEIOP) in mice and rats is accomplished by 
cannulation of the anterior chamber with physiological saline for defined periods of 
time, which results in retinal and optic nerve functional deficits, and subsequent RGC 
death37.  While useful for some experiments, the AEIOP model more closely 
replicates features of ACG and not POAG, therefore, it was not used for these 
experiments.  In addition, there are several models of chronic ocular hypertension 
(COH), where the intraocular pressure rises gradually, as compared to acute ocular 
ischemic models38.  The IOP in COH models is raised by various methods, but the 
underlying theme is decreased AH outflow from the trabecular and uveoscleral 
pathways.  The IOP in these models can be quantified using tonometry, which is the 
force (in mmHg) it takes to flatten a piece of the cornea with a prism39.  One such 
model of COH is induced by laser cauterization of the trabecular meshwork (TM) and 
episcleral veins in the region of the limbal radius40, 41.  Other variants of this model 
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either cauterize42, 43, ligate with sutures44, or destroy by injection of hypotonic saline45 
several limbal-derived episcleral veins to increase IOP.  While these variants are 
advantageous for the same reasons we detail below for the laser cauterization 
model, they suffer from some shortcomings.  The primary disadvantage is that there 
is substantially more mechanical manipulation of the eye necessary to create the 
model, whereas there is no mechanical manipulation of the eye in the laser 
cauterization model, which reduces potential variability.  Additionally, researchers 
have injected latex microspheres into the anterior chamber with the purpose of 
obstructing AH outflow, which was shown to increase IOP46.  The latex microsphere 
obstruction of the outflow pathways is very similar to one of the few genetic models, 
the DBA/2J mouse, a model for pigmentary glaucoma16.  While genetic models are 
useful, this particular model has a very prolonged development of retinal 
degeneration, coupled with variability in the amount of degeneration observed in 
individual animals, making the DBA/2J mouse less than ideal for the experiments 
presented here.  Finally, optic nerve crush47 and axotomy48 models have been used 
to study RGC death.  These crush/ axotomy models are particularly useful in 
modeling the degeneration of RGCs because a substantial number of cells are 
undergoing apoptosis at one time, as compared to models with a gradual increase in 
IOP, however, they are not useful for modeling glaucoma over extended timecourses 
due to the rapid degeneration of RGCs. 
 The rodent models of glaucoma replicate the key feature of the human 
disease, which is a loss of RGCs.  Several studies have shown that RGCs die after 
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an increase in IOP in rodent experimental glaucoma38, 42, 45, 46, 48, and that this cell 
death can be ascribed to apoptotic mechanisms48.  In addition, the relative spatial 
and temporal pattern of RGC death mirrors glaucomatous human eyes.  This pattern 
of degeneration after insult shows the death of RGCs in the retina is linear, with 
peripheral RGCs more susceptible to cell death, although apoptosis of RGCs is 
visible in all locations of the retina49.  Furthermore, the degeneration observed in 
these models is capable of being controlled with drugs used in human patients that 
decrease the production of AH50.  Taken together, these models provide reliable, 
reproducible models for investigating the cellular processes involved in RGC death 
in glaucoma, and for evaluating neuroprotective strategies for retinal neurons in 
glaucomatous eyes.   
In the experiments presented in this dissertation we use the COH rat model of 
glaucoma created by the laser caut/erization of trabecular meshwork and episcleral 
veins.  This model has many benefits including simplicity of induction, and ability to 
do comparisions between treatment groups, as the onset of degeneration is the 
same in each animal, which is not the case with genetic models of glaucoma.  The 
prolonged degeneration in the COH model of glaucoma as compared to axotomy 
and ischemic models also make it useful for these experiments.  In addition, rigorous 
histological and functional analysis has been carried out in this model, which gives a 
baseline for comparison41 .   
 15 
In Vitro Models to Study Glaucoma 
The primary models for glaucoma in rats are those in which IOP is increased 
above normal levels51, as we have discussed.  While these models have proved 
invaluable for researchers, the cost of animal care, as well as the labor involved in 
generating the models and carrying out the experiments is prohibitive to large-scale 
assays of potential neuroprotective compounds.  Alternatives to generating in vivo 
glaucoma models include retinal explants and purification of RGCs from dissected 
eyes52-55, which is again labor intensive and costly.  Using a transformed retinal 
ganglion cell line, the RGC-5s, can circumvent these problems for some studies.  
The RGC-5s are retinal ganglion cells that have been transformed with the ψ2 E1A 
virus, and maintained as an adherent, mitotic population of cells.  Initial 
characterization of the RGC-5s revealed expression of the neuronal markers Thy-1, 
Brn3c, Neuritin, as well as NMDA and GABA-B receptors56.  The RGC-5s initially 
proved useful in modeling the apoptotic events of RGCs with respect to serum 
deprivation57, oxidative stress58, glutamate excitotoxicity59, as well as cell death 
resulting from hydrostatic pressure60.  While the rapid growth of these cells allows for 
robust expansion of the cell line, it creates problems analyzing neuroprotection 
experiments, as the presence of mitotic cells confounds the results.  A recent 
discovery by Frassetto et al. determined that treating RGC-5s with the general 
kinase inhibitor staurosporine (SS) induces these cells to become non-mitotic, highly 
branched cells, with sustained outward currents consistent with neuronal cells61.  
With this advance it is now possible to reliably use RGC-5s as models of retinal 
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ganglion cells to assess potential neuroprotective factors and delivery systems in a 
reproducible, high-throughput manner without the confounding variables that highly 
mitotic cells would introduce into these types of experiments. 
Brain-Derived Neurotrophic Factor 
In these studies we use a biological molecule delivered through cellular 
vehicles to the retina to prevent the degeneration of retinal ganglion cells, as well as 
preserve retinal function, in a rodent experimental glaucoma model.  The molecule 
we use is brain-derived neurotrophic factor (BDNF), a member of the widely studied 
neurotrophin family.  The other neurotrophins in this family include nerve growth 
factor (NGF), neurotrophin 3 (NT3), and neurotrophin 4/5 (NT4/5).  The neurotrophin 
family is involved in a number of cellular processes, including cell proliferation and 
survival; cell migration; axonal and dendritic outgrowth and remodeling; synapse 
formation, function, and plasticity; as well as cytoskeletal assembly and 
remodeling62-67.   
BDNF is synthesized as a precursor, pro-BDNF, a 32-kDa molecule that is 
glycosylated and glycosulfated at the N-terminus.  Pro-BDNF is cleaved within the 
trans-golgi network to yield a 14-kDa mature BDNF protein68, 69.  The cleavage of the 
precursor molecule increases the biological activity of BDNF, however, pro-BDNF 
isoforms are capable of binding to and activating receptors.   
Neurotrophins signal through the high affinity Trk family of receptors, as well 
as the low affinity p75 receptor62-64.  BDNF preferentially binds to its high affinity 
receptor TrkB, although can still signal through other Trk receptors70, 71.  Two Trk 
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receptors dimerize and phosphorylate one another following ligand binding, thereby 
activating specific tyrosine residues.  The activated tyrosine residues can 
subsequently phosphorylate two additional tyrosine residues to serve as attachment 
sites for Shc and Phospholipase C (PLC), which have multiple downstream effects 
on cellular function62.  In cultured RGCs BDNF neuroprotection has been shown to 
be mediated by a combination of activated phosphatidyl-inositol-3’ kinase (PI-3-K) 
and Mitogen-activated protein kinases (MAPK), as well as suppression of apoptotic 
signals72.  As we will discuss, BDNF and its receptor are regulated in retinal disease 
states, and may be neuroprotective for compromised retinal neurons, making it a 
very interesting molecule to study in the context of glaucomatous optic neuropathies.    
BDNF and Disease 
BDNF and its receptor TrkB are important for ganglion cell development73, 74 
and survival75, 76.  This ligand-receptor is found in a wide variety of cells within the 
neural retina.  Many groups have shown that BDNF is expressed by RGCs, 
amacrine cells, INL neurons77-80, cells of the lamina cribrosa, and optic nerve head 
(ONH) astrocytes81.  The neurotrophin receptor TrkB is expressed in the optic fiber 
layer, RGCs, Müller glial cells, photoreceptor outer segments, cells of the lamina 
cribrosa, and ONH astrocytes in the normal, healthy adult neural retina78-80, 82, 83.  
It is also important to note that neurotrophins and their receptors are highly 
expressed in the brain84, and can be transported in a retrograde fashion from RGC 
targets in the brain, via an internalized receptor-ligand complex77, 85, 86  that is capable 
of activating signaling pathways from the distal portions of the cell to the soma87, 88.  
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The retrograde transport of BDNF has been a subject of intense study in rodent 
models of glaucoma.  Researchers have shown that retrograde transport of BDNF 
from target structures is severely compromised in rats with increased IOP, 
suggesting a potential physiological axotomy where BDNF cannot reach its intended 
target.  The amount of radiolabeled BDNF transported from the colliculus of 
experimental rats decreased between 50 and 83% following an increase in IOP30, 31.  
This suggests that using cellular vehicles to deliver supplemental BDNF to the neural 
retina to replace neurotrophins that do not reach their cellular targets is a useful 
treatment strategy.   
BDNF and TrkB Modulation in Retinal Disease States 
BDNF and its receptor TrkB may be involved in mediating neuroprotective 
effects to retinal neurons in a wide variety of ocular diseases.  Several studies have 
shown that TrkB is transiently up regulated, and then quickly down regulated in 
several models of glaucoma.  The upregulation of TrkB following insult occurs 
quickly, as Quigley et al. report that TrkB begins to accumulate in the cytoplasm of 
RGCs 4 hours after induction of COH30.  Other researchers using the COH model 
have noted that the receptor remains at steady levels for the duration of the 
experiment for 7-28 days post induction, while BDNF expression does not increase 
until 28 days post induction80.  The same trend of early TrkB upregulation, followed 
by a steady decrease in expression has been observed in rats with optic nerve 
axotomy82, as well as in ischemia-reperfusion models79.  Additionally, BDNF 
expression upregulation, coupled with the receptor down regulation has also been 
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shown for cells in the lamina cribrosa using a model of glucose depletion89, although 
in models of elevated intraocular pressure BDNF is undetectable in the optic nerve 
head 7 days after pressure has been elevated90. 
Evidence in multiple disease models suggests that the prolonged increase in 
expression of BDNF does not coincide with the rapid, transient, up-regulation of its 
receptor TrkB.  It is possible that the up-regulation of BDNF in the retina following 
disease is an innate neuroprotective strategy, but fails to realize this protection to the 
cells due to asynchronous upregulation of ligand and receptor.  We propose that 
delivering BDNF at a timepoint when the receptor is up regulated, as well as 
providing a continuous supply of BDNF to the retina to supplement the BDNF lost 
from decreased retrograde transport will result in preservation of retinal architecture 
and function.  
Reactive Oxygen Species and Excitotoxicity  
 Aside from cell death due to loss of trophic support and increased IOP, cell 
death in glaucoma may be due in part to excitotoxic over stimulation of excitatory 
amino acid receptors mediated by glutamate33, 91, 92.  When injected into the retina, 
glutamate induces cell death in RGCs in a similar pattern to that of RGCs in 
glaucomatous eyes92.  It is hypothesized that glutamate is released from apoptotic 
RGCs in glaucomatous eyes, as increased vitreous glutamate levels have been 
demonstrated in rat33, 93, 94 and canine95 glaucoma models.  The extracellular 
glutamate detected in these models may be due to a defect in the glutamate 
transporter in glaucomatous eyes, which decreases glutamate re-uptake from 
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synapses96-98.  This extracellular glutamate mediates RGC death via NMDA and non-
NMDA glutamate receptors on the cell body99, or through interactions with 
compromised optic nerves100.  It has been shown that glutamate induces RGC death 
by activation of caspases101,  an may involve the extracellular-signal related 
kinase102.        
Another cause for cell death in glaucomatous retinas is the presence of 
excessive reactive oxygen species (ROS)103.  ROS are typically generated in the 
mitochondria of retinal neurons as byproducts of cellular metabolism32.  Patients with 
POAG showed a high incidence of mitochondrial damage104, DNA damage105,  a 
decrease in antioxidants, and an increase in oxidative radicals106, suggesting 
multiple roles for oxidative radicals in glaucomatous optic neuropathies.  In axotomy 
models of RGC damage a mitochondrial specific upregulation of the superoxide 
anion was observed, which correlated very closely with activation of caspase 
mediated RGC death107.  Additionally, oxidant-mediated mitochondrial damage 
results in a decrease in cellular ATP, which reduces cell viability108.  ROS may also 
contribute to retinal damage in glaucoma by making RGCs more susceptible to 
apoptosis, and by damaging the trabecular meshwork leading to an increase in 
IOP109, 110.  Finally, ROS have the potential to oxidatively modify proteins, which may 
give them novel functions, resulting in RGC death32, 103.  In our experiments, we 
demonstrate BDNF delivered by cellular vectors is capable of providing 
neuroprotection to models of retinal neurons that have been subjected to glutamate 
or ROS induced cell stress.  
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Neurotrophins and Treatment of Retinal Damage 
The neurotrophin family has been extensively studied for the ability to 
preserve retinal neurons after exogenous application in various models of retinal 
disease111.  It has been shown that BDNF is capable of preventing cell death in 
cultured mammalian RGCs isolated from developing retinas in vitro 75, 76.  
Subsequent experiments in vivo have successfully used intravitreal injections of 
recombinant BDNF to protect RGCs from apoptosis following chemically induced 
hypoxia112, as well as axotomy of the optic nerve113-115.   
Delivering BDNF into compromised retinas using a reliable long-term delivery 
method has been a subject of intense study.  BDNF has been delivered to RGCs116 
and Müller glial cells117 using viral constructs, which has been shown to be effective 
in the anatomical preservation of RGCs in the laser cauterization model of 
glaucoma.  BDNF has also been shown to work synergistically with other factors 
such as free radical scavengers118, or factors released from damaged lens119 to 
preserve RGCs from apoptosis.  Additional methods used to deliver other 
neuroprotective factors to diseased retinas include biodegradeable microspheres120, 
and engineered neural progenitor121 or Schwann cells122.   
While many of these experiments are successful in preserving some retinal 
architecture, very few studies have examined retinal function and retinal architecture 
of treated eyes to assess the level of neuroprotection.  Also, these experiments use 
repeated injection of a recombinant BDNF protein, or delivery of BDNF in an intra-
cellular fashion by using a viral construct.  While viral constructs are minimally 
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invasive, they are unreliable in targeting specific cell types.  We believe that extra-
cellular long-term application of BDNF via a cellular vector is an ideal method to 
provide long-term neuroprotection to the retina.     
Cellular-Based Retinal Therapies 
A significant effort has been made to develop cell-based therapies to treat 
retinal disease using a variety of cells derived from distinct tissues.  Cells that have 
been identified as potentially useful for these types of therapies include: embryonic 
stem cells123, retinal progenitor and precursor cells124-127, neural progenitor cells 
derived from non-ocular tissues121, 124, 128-132, Schwann cells derived from the 
peripheral nervous system122, 133-135, fibroblasts133, proliferating retinal pigment 
epithelial cells136, 137, limbal and conjunctival epithelial stem cells138, and sheets of 
retinal derived tissue139, 140.  It has been shown that progenitor124, 128-130, 132, 141 and 
embryonic stem123 cells transplanted into developing and damaged retinas have the 
ability to survive following transplantation and differentiate into neural-like cells that 
express proteins consistent with retinal neurons.  It was subsequently shown that 
transplanting committed photoreceptor precursors lead to development of mature 
photoreceptors that developed synaptic connections within the neural retina, and 
lead to increased visual function in a model of retinal degneration126.  Additionally, 
human progenitors secreting GDNF121, naïve Schwann cells133, 135, and BDNF- or 
GDNF-secreting Schwann cells122 have been shown to prevent degeneration and 
preserve visual function in models of retinal disease.  While interesting and 
encouraging results have been obtained using these experimental approaches, they 
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suffer from drawbacks that make them less than ideal for clinical applications.  The 
major obstacle with many of the central nervous system (CNS) derived cell lines 
from adult tissues is generating enough cells to use for therapies from a single 
donor.  Even if enough cells are obtained, the issues of immune compatibility and 
graft rejection are still present.  If cells were derived from fetal or neonatal tissue for 
therapeutic reasons, there are major moral and ethical concerns to be taken into 
consideration, in addition to immune compatibility with the host tissue.  These 
problems are also present with retinal sheet transplantation.  Embryonic stem cells 
again raise moral and ethical concerns, and have the potential to cause damage to 
the host tissue by the formation of tumors142.  We propose an alternative cell line, 
mesenchymal stem cells (MSCs), to be used as cellular vehicles for the treatment of 
retinal disease. 
We believe that MSCs are ideal sources of stem cells for CNS-directed cell-
based therapies due to their plasticity143, and ease of isolation and expansion144, 145.  
Several groups have demonstrated the plasticity of MSCs by showing that they were 
able to differentiate into neural-like cells146-150 in vitro; some of which displayed 
electrophysiological properties consistent with mature CNS neurons148, 150.  For cell-
based therapies to be effective, it is essential that the transplanted cells are able to 
thrive in the host environment.  Previous studies have shown MSCs have the 
capacity to survive, migrate, and integrate into CNS environments following 
transplantation149, 151-154.  Furthermore, naïve, unmodified, MSCs have been shown to 
have neuroprotective effects when transplanted into mouse models of retinal 
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degeneration155-157.  Due to MSCs rapid expansion and ease of use it is conceivable 
to use MSCs in an autologous fashion, in which cells are isolated from a donor, 
genetically modified, and transplanted into the same host.  These strategies are 
attractive, as immune rejection of transplanted material becomes less of an issue, as 
well as bypassing moral and ethical objections to using embryonic, neonatal, and 
fetal derived stem cells.  For these reasons we propose that MSCs are 
adventageous for use as cellular vehicles to deliver neuroprotective substances to 
diseased retinas. 
Viral Constructs 
 In the studies presented here we use lentiviral constructs to engineer MSCs 
to produce the neuroprotective factor BDNF.  Lentiviral constructs are produced by 
packaging a gene of interest in a non-replicative retroviral skeleton158, 159.  These viral 
constructs typically contain a glycoprotein from the vesicular stomatitis virus, which 
allows the virus to infect a broad range of cells160.  Lentiviral vectors have been 
investigated for use in gene therapy, as gene transfer has shown to be effective in 
transduction of the retinal pigment epithelium to protect cones from retinal 
degeneration161.  Lentiviral-mediated gene transfer to retinal neurons, however, is not 
a viable option due to low infection efficiency of the virus to mature retinal neurons in 
vivo162.  Intravitreal injections of adenoviral or adeno-associated viral vectors have 
proven useful in the transduction of retinal neurons163, 164, and neuroprotective gene 
delivery by these vectors to retinal neurons protects them in models of retinal 
disease117, 165-168.  A concern with this type of treatment is that these vectors have the 
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Figure 2. Representative ERG traces for 
scotopic rod (A), scotopic maximum combined 
response (B), oscillatory potentials (C), 
photopic cone (D), and flicker ERG (E).  
potential to cause retinal dysfunction169, and are currently not approved for use in 
human clinical therapy.  Lentivirus can, however, be used to engineer stem cells ex 
vivo for transplant into damaged or diseased tissue170.     These vectors are ideal for 
the potential treatments presented here, as they have very robust rates of infection 
and have the potential for high scale production in order to make enough construct 
for use in medical treatments171.    
Retinal Functional Measurements 
 In these series of experiments we use non-invasive functional measures to 
evaluate the 
preservation of retinal 
function following 
transplantation of 
engineered MSCs.  
Electroretinogram 
(ERG) responses are 
electrical representations of 
the functional connectivity 
between neurons that are recorded at the cornea (Fig 2).  A typical ERG protocol is 
a bright flash of light, which elicits a response from all retinal neurons, and can be 
broken down into its component parts.  The a-wave is measured from the onset of 
light stimulation to the most negative component of the recording.  The a-wave 
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reflects the function of photoreceptors in the ONL172.  The ERG b-wave is measured 
from the trough of the a-wave to the most positive component of the trace, and 
reflects inner retinal neuron function.  The b-wave contains oscillatory potentials that 
can be examined using another ERG protocol, which reflects the signaling between 
RGCs and neurons of the INL173.  Additionally, the contribution of rods and cones to 
retinal function can be isolated using specific ERG protocols and light stimuli.  
Baseline ERG responses have been established in healthy rodents174-176, and these 
responses have subsequently been shown to have defects40, 41, 177-180 in hypertensive 
eyes that are graded with respect to the IOP181.  The ERG is useful as a diagnostic 
clinical tool, as it has been demonstrated that the defect in the ERG b-wave can be 
correlated to the amount of retinal ischemia present173.  Electroretinograms are a 
sensitive measure of retinal function, and are useful for neuroprotection experiments 
as ERGs are capable of detecting subtle preservation of visual function following 
neuroprotective therapies121, 182-184. 
 Another measure of retinal and optic nerve function is computerized 
pupillometry measuring the pupillary light reflex (PLR), which constricts the iris in 
response to light (Fig 3).  Pupillometry can measure direct responses to light, or 
consensual responses from fellow eyes.  The stimulus responsible for mediating the 
PLR travels from the retina to the optic nerve into the Edinger-Westphal and 
pretectal olivary nuclei.  This signal is then propagated back to the ciliary ganglion 
via the oculomotor nerve, which constricts the direct and consensual eye.  The PLR 
is intimately related to a photopigment containing class of RGCs, which can mediate 
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Figure 3. Diagram of direct and consensual 
pupillary light constriction pathway.  Adapted 
from www.umed.med.utah.edu. 
the PLR independently of rods and cones185, 186.  The PLR has been characterized in 
healthy rodent eyes174, 175, and has been shown to have severe defects in 
hypertensive eyes40, 41.  Pupillometry has been shown to be useful in determining the 
extent of functional rescue following neuroprotective transplants to rat models of 
retinal degeneration136.  Additionally, assessment of the PLR, and iris responses to 
light are common clinical assessments of the progression or extent of human optic 
neropathies, particularly glaucoma187-190.    
Summary 
 Glaucoma is a 
complex disease, with many 
factors contributing to RGC 
cell death.  Developing 
neuroprotective strategies to 
attenuate RGC is essential to 
prevent loss of vision.  The 
experiments outlined in this 
dissertation demonstrate a novel 
treatment strategy to prevent 
RGC loss in glaucomatous eyes is the delivery of the neuroprotective protein BDNF 
via a cellular vehicle, the mesenchymal stem cells.   
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Abstract  
Purpose. The purpose of this study was to determine if staurosporine (SS) 
differentiated RGC-5 cells were susceptible to the cellular stressors hydrogen 
peroxide (H2O2) and glutamate, in order investigate their use as an in vitro model of 
glaucoma.  Additionally, we investigated the ability of mesenchymal stem cells 
(MSCs) to serve as a cellular-based delivery system to deliver brain-derived 
neurotrophic factor (BDNF) to compromised cells. 
Methods.  RGC-5 cells were differentiated with SS.  Immunocytochemical analysis 
was used to assess RGC-5 differentiation using markers specific for retinal ganglion 
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cells in the neural retina.  Following differentiation, RGC-5s were subjected to the 
cellular stressors glutamate and H2O2, and remaining cells were quantified.  Brain-
derived neurotrophic factor (BDNF) was added to glutamate or H2O2 treated RGC-5s 
to examine its neuroprotective capacity, using MSCs engineered to secrete BDNF by 
transduction with a lentiviral construct.  Remaining RGC-5s after co-culture with 
engineered MSCs were subsequently quantified.  Additionally, recombinant human 
BDNF (rhBDNF) was added to cultures treated with cellular stressors as a positive 
control.  
Results.  After SS differentiation a significant increase in the proportion of RGC-5s 
expressing the RGC markers TuJ 1 and Brn3a after 3 days was observed.  In 
addition, RGC-5s developed complex morphologies, as compared to control, carrier 
solution-treated controls.  Differentiated RGC-5s also highly expressed the BDNF 
receptor TrkB.  It was determined that there were significant decreases in remaining 
RGC-5s following treatment with glutamate and H2O2, as compared to carrier-
solution treated cells.  Furthermore, application of BDNF released from BDNF 
secreting MSCs, or purified BDNF prevented the glutamate- or H2O2-mediated 
decrease in RGC-5 cells.  
Conclusion.  We have demonstrated that SS differentiated RGC-5s have 
phenotypic and morphological properties consistent with retinal neurons, and they 
respond to the cellular stressors glutamate and H2O2 in similar fashion.  Additionally, 
we have demonstrated BDNF can attenuate RGC-5 cell loss due to these stressors.  
Our results demonstrate that MSCs are effective vehicles to deliver BDNF to 
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compromised neural-like cells in an in vitro disease model, suggesting this may be a 
useful in vivo treatment for retinal diseases.  
Introduction 
Glaucomas are a family of ocular diseases that lead to retinal ganglion cell 
(RGC) death, optic nerve degeneration, and subsequent loss of visual function1.  
Developing neuroprotective strategies to attenuate RGC death are imperative, as it 
is estimated that 60.5 million people world-wide will have glaucoma by the year 
2010, increasing to 79.6 million by 20202.  Extensive research suggests primary 
degeneration of RGCs in glaucoma induces secondary degeneration of adjacent 
RGCs, although the etiology for many subtypes of glaucoma have not been 
elucidated3.  Secondary degeneration of RGCs is thought to be mediated, in part, via 
glutamate excitotoxicity3-6, as elevated glutamate levels have been reported in the 
vitreous of canine7 and rat8 models of glaucoma.  Another secondary factor that 
contributes to RGC death in glaucomatous eyes is the presence of excessive 
reactive oxygen species (ROS), which are capable of inducing DNA damage and the 
oxidative modification of proteins, which leads to cellular dysfunction and 
subsequent cell death9-12.  Developing neuroprotective approaches that can preserve 
retinal cell integrity following insults with ROS and glutamate are important 
strategies, as these treatments would be applied long after the initial onset of 
glaucoma, and at the stage of glaucoma where RGCs are most likely to be affected 
by glutamate excitotoxicity and ROS mediated oxidative damage.   
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Studying glaucoma requires reproducible, reliable models.  The primary 
models for glaucoma in rats are those in which intraocular pressure is increased 
above normal levels13.  While these models have proved invaluable for researchers, 
the cost of animal care, as well as the labor involved in generating the models and 
carrying out the experiments is prohibitive to large-scale assays of potential 
neuroprotective compounds.  Alternatives to generating in vivo glaucoma models 
include retinal explants and purification of RGCs from dissected eyes14-17, which are 
also labor intensive and costly.  Using a transformed retinal ganglion cell line, the 
RGC-5s, can circumvent these problems for some studies.  The RGC-5s are a 
retinal ganglion cell line that have been transformed with the ψ2 E1A virus, and 
maintained as an adherent, mitotic population of cells that retains some 
characteristics of retinal ganglion cells18.  The RGC-5s initially proved useful in 
modeling the apoptotic events of RGCs with respect to serum deprivation19, oxidative 
stress20, glutamate excitotoxicity21, as well as cell death resulting from hydrostatic 
pressure22.  While the rapid growth of these cells allows for robust expansion of the 
cell line, it creates problems analyzing neuroprotection experiments, as the presence 
of mitotic cells confounds the results.  A recent discovery by Frassetto et al. 
determined that treating RGC-s with the general kinase inhibitor staurosporine (SS) 
induced these cells to become non-mitotic, highly branched cells, with some 
electrophysiological properties consistent with retinal neurons23.  With this advance it 
is now possible to reliably use RGC-5s as models of retinal ganglion cells to assess 
potential neuroprotective factors and delivery systems in a reproducible, high-
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throughput manner without the confounding variables that highly mitotic cells would 
introduce into these types of experiments. 
 A candidate for neuroprotection of RGCs in glaucomatous eyes is brain-
derived neurotrophic factor (BDNF), a 14 kDa protein24 that signals through its high 
affinity TrkB receptor25.  Brain-derived neurotrophic factor has been shown to be 
essential for correct RGC development26, 27, and survival of RGCs in vitro28, 29.  Bolus 
injections of BDNF have also been shown to be neuroprotective for retinal neurons 
in models of retinal disease, as well as optic nerve axotomy30-36.  Additionally, viral 
mediated transfer of BDNF to damaged retinas has been shown to be 
neuroprotective for RGCs in models of glaucoma37, 38.  While these results are 
encouraging, it is important to address the prolonged delivery of BDNF to 
glaucomatous retinas, as repeated injections into the eye, or viral mediated transfer 
are not viable treatment options for a chronic ocular neuropathy in human patients.  
Therefore, it is essential to develop a minimally invasive treatment that is capable of 
prolonged delivery of BDNF to glaucomatous retinas.   
We propose that cell based delivery is a useful strategy to provide BDNF, or 
other neuroprotective factors, to glaucomatous eyes.  Mesenchymal stem cells 
(MSCs) are excellent cellular vehicles to deliver BDNF to damaged retinas as they 
are an especially plastic population of cells39 that are easily isolated based on 
adherence to culture chambers40, and provide a potential source for cells that can be 
easily obtained and engineered for autologous transplants.  Mesenchymal stem cells 
bypass the ethical concerns typically associated with embryonic, fetal, and neonatal 
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derived cells, and the difficulty associated with deriving adult progenitors from CNS 
tissues.  In addition, MSC have the ability to survive and migrate when transplanted 
to CNS tissues41-45, differentiate into neural-like cells in vitro41, 45-47, and display 
electrophysiological properties consistent with mature neurons48, 49.  Furthermore, 
naïve MSCs have also shown the potential to be neuroprotective when transplanted 
into models of retinal degeneration50-52.  Taken together, these results indicate that 
MSCs are excellent candidates for genetic engineering and autologous transplants 
into damaged CNS environments.   
  The purposes of the experiments presented in this study are twofold.  First, 
we demonstrate SS differentiated RGC-5s are a useful in vitro model of retinal 
ganglion cells and are advantageous to study aspects of cell death, with respect to 
glaucomatous optic neuropathies.  We have shown that these cells are capable of 
expressing markers consistent with RGCs.  Furthermore, the SS differentiated RGC-
5s were susceptible to both H2O2-mediated oxidative stress, and glutamate induced 
cell loss, as observed in RGCs in vivo 9, 12, 17, 53.  The second purpose was to 
demonstrate the feasibility of using MSCs to deliver neuroprotective factors to RGCs.  
We have demonstrated that BDNF released from MSCs engineered with lentiviral 
constructs was sufficient to protect RGC-5s from glutamate- or H2O2-mediated cell 
loss.  To substantiate our observations, rhBDNF was added to SS differentiated 
RGC-5s treated with glutamate or H2O2 as a positive control.  This application was 
also shown to prevent cell loss of RGC-5s present.  Taken together, these results 
demonstrate RGC-5s can serve as a model of retinal ganglion cells, and that MSCs 
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are an excellent population of cells that may have major clinical implications as 
delivery systems for neuroprotective factors to provide sustained treatment for CNS 
diseases following transplantation. 
Materials and Methods 
RGC-5 Maintenance and Differentiation 
The RGC-5 cells (a generous gift from N. Agarwal, University of North Texas) 
were maintained as an adherent cell line in uncoated T-75 tissue culture flasks.  
RGC-5s were grown in complete media containing DMEM (1 g glucose/ L, Gibco) 
10% fetal bovine serum (FBS; SH30071.03, Hyclone, Logan, UT), L-glutamine (4 
mM, 25038-081, Gibco, Grand Island, NY) and a penicillin (100 U/mL)/ streptomycin 
(100 µg/mL) solution (P0781, Sigma, St. Louis, MO).  Cells were grown to 80% 
confluency and were gently lifted from the flask using 2 mL 0.05% Trypsin-EDTA 
(25300-054, Gibco) and placed in a 37°C incubator for 30 seconds.  Trypsin was 
diluted with fresh media, and RGC-5s were centrifuged at 800g for 5 minutes to 
pellet the cells.  Pellets were re-suspended in fresh media and split into new flasks at 
a ratio of 1:10.  RGC-5 cultures were fed every other day by supplementing the flask 
with fresh growth media.     
 RGC-5s were induced to differentiate into highly branched, non-mitotic cells 
using a protocol developed by Frassetto et al23.  Briefly, RGC-5s were cultured as 
previously described and plated onto glass coverslips coated with an entactin-
collagen-laminin substrate (ECL, 10µg/mL, 08-110, Chemicon, Temecula, CA).  
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Cells were allowed to adhere to the coverslip for 1 hour at 37°C.  Cells were 
subsequently treated with the general kinase inhibitor staurosporine (1 µM, ALX-380-
014-C100, Alexis, San Deigo, CA) for 1 hour.  Following differentiation, media was 
changed to fresh growth media and RGC-5s were grown an additional 3 days and 
analyzed for expression of neuronal markers using immunocytochemistry, or used 
immediately for subsequent experiments. 
Bromo-deoxyuridine Incorporation Analysis  
 Control or SS-differentiated RGC-5s were incubated with 5 µM Bromo-
deoxyuridine (BrdU) for 6 hours.  BrdU containing media was removed, fresh media 
added, and cells were allowed to grow overnight.  Cells were then fixed with 4% 
paraformaldehyde in 0.1 M PO4 buffer (pH 7.4).  Following rinses in phosphate-
buffered saline (PBS; 137 mM NaCL, 2.68 mM KCl, 10.14 mM Na2HPO4, 1.76 mM 
KH2PO4, pH 7.2) cells were incubated in 2 N HCl for 15 minutes at 37° C.  HCl was 
inactivated by incubation with 0.1 M sodium borate for 15 minutes at room 
temperature.  BrdU incorporation was detected with an anti-BrdU antibody (1:250, 
Accurate Chemical, Westbury, NY).  The number of BrdU immunolabeled cells was 
counted in 5 fields on each coverslip at 10X magnification.  The percentage of B rdU 
positive cells was calculated by dividing the total number of BrdU immunoreactive 
cells by the total number of cells as determined from separate images of the nuclear 
stain 4’, 6’-diamidino-2-phenylindole, dilactate (DAPI, 1 µg/ mL, D3571, Sigma) for 
three separate culture sessions. 
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Rat Mesenchymal Stem Cells  
Rat MSCs (Tulane Center for Gene Therapy, New Orleans, LA) were 
maintained as an adherent cell line in α-MEM media (12561-049, Invitrogen) 
containing 20% hybridoma qualified FBS (S11595, Atlanta Biologicals, Norcross, 
GA), 2 mM L-glutamine, and antibiotic-antimycotic (1%,15240-096, Invitrogen; 
10,000 U/mL penicillin, 10,000 µg/mL streptomycin, 25 ng/mL amphotericin B).  
Cells were maintained as low-density cultures at 75-150 cells/ cm2.  When cultures 
reached 70-80% confluency MSCs were gently lifted from the dish using 0.25% 
trypsin, 0.1% EDTA solution (Invitrogen).  Fresh media was added to inactivate the 
trypsin, and MSCs were pelleted at 800g.  MSCs were subsequently plated into 150 
mm culture dishes at 75-150 cells/ cm2.  Cultures were fed by supplementing the 
dish with fresh media every other day.   
Engineering Stem Cells Ex-Vivo with Lentiviral Vectors 
Mesenchymal stem cells were engineered to produce and secrete the 
neurotrophic factor BDNF using lentiviral vectors.  Briefly, MSCs were plated in 6 
well plates at a density of 1000-1200 cells per well and allowed to adhere for 12 
hours.  After adhering to the plate the growth media was substituted in each well with 
α-MEM containing 2% FBS and 12 µg/ml sequabrene (152667, Sigma).  Two 
separate lentiviral constructs encoding 1) BDNF (LV-BDNF) and 2) green fluorescent 
protein (GFP, LV-GFP) were added simultaneously to MSCs at a multiplicity of 
infection (MOI) of 15 for each construct.  A population of control MSCs was 
engineered with only the LV-GFP construct at an MOI of 30 to match the viral titer of 
 62 
the BDNF/GFP engineered MSCs.  Viral particles were removed after 8 hours of 
exposure, and media was changed to fresh growth media.  Engineered MSCs were 
subsequently maintained as previously described. 
Neurotrophin Bioactivity Assay 
 All animal studies were conducted in accordance with the ARVO Statement 
for the Use of Animals in Ophthalmic and Vision Research, and had approval of the 
Iowa State University Committee on Animal Care.  Primary cultures of rat embryonic 
day 17 (E17) dorsal root ganglia (DRG) were used to assess the bioactivity of BDNF 
released from MSCs, as DRGs have been shown to elongate neurites in response to 
BDNF exposure54, 55.  Briefly, E17 rat pups were decapitated, rinsed in ice-cold 70% 
ethanol, and subsequently placed in ice-cold DMEM.  Spinal columns were 
dissected via a ventral approach in ice-cold L-15 media (21683-027, Invitrogen), and 
lumbar DRGs were dissected and pooled.  Following dissection, DRGs were rinsed 
with ice-cold L15 and transferred to warm DRG growth media containing DMEM, L-
glutamine, penicillin-streptomycin, and 10% FBS.  Three to four DRG explants were 
transferred in approximately 75 µL of media onto poly-L-ornithine coated 12 mm 
coverglass placed into wells of 24 well culture plates.  DRGs were allowed to adhere 
for 8 hours, and wells were subsequently flooded with experimental media.  Media 
that DRGs were grown in included MSC growth media, MSC media conditioned by 
BDNF-MSCs or GFP-MSCs, respectively, or MSC media containing 100 ng/ mL 
recombinant human BDNF (rhBDNF, 450-02, Peprotech, Rocky Hill, NJ).  Explants 
were allowed to grow for an additional 48 hours, and subsequently fixed with 4% 
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paraformaldehyde (pH 7.4).  To visualize and quantify neurite outgrowth, cultures 
were stained with an anti-neurofilament antibody (RMO.308, 1:50, Virginia Lee, 
University of Pennsylvania), as described in the next section.  Images of each DRG 
were captured using a 10X objective, and montage images were prepared.  Each 
montage image was presented to five naïve observers in order to judge the extent 
and density of neurite outgrowth in each condition.  Each DRG was scored on a 
scale from 1-5; with 1 representing little neurite growth in terms of length and 
density, and 5 representing long, dense neurite arborization from the DRG.    Data 
from this analysis was pooled and statistical analysis was performed.   
 
Immunocytochemical Analysis 
 Cultures were fixed with 4% paraformaldehyde in 0.1 M PO4 buffer.  Following 
rinses in filtered PBS, cells were incubated in blocking solution containing 5% normal 
donkey serum (NDS, 017-000-121, Jackson ImmunoResearch, West grove, PA), 
0.04% bovine serum albumin (BSA, A9647, Sigma), and 0.04% Triton X-100 to 
eliminate non-specific antibody labeling.  Coverslips were incubated in the primary 
antibodies: anti-TuJ 1 (1:250, R&D Systems, Minneapolis, MN), anti-Brn3a (1:100, 
Chemicon), anti-TrkB (1:100, Santa Cruz, Santa Cruz, CA), or anti-BDNF (1:100, 
Santa Cruz), diluted in blocker overnight at 4°C.  Coverslips were then rinsed in PBS 
containing 0.1% Triton X-100.  A donkey anti-mouse Cy-3 conjugated secondary 
antibody (1:150, 711-175-152, Jackson ImmunoResearch), was applied for 2 hours, 
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and subsequently rinsed in filtered PBS.  DAPI (1 µg/mL, Sigma) and Alexa-488 
Phalloidin (5 U/mL A-12379, Molecular Probes, Eugene, OR) were diluted in PBS 
containing 0.04% Triton X-100 and incubated for 30 min at room temperature in 
order to visualize nuclei and the F-actin cytoskeleton, respectively.  Coverslips were 
subsequently rinsed with PBS and mounted in Vectashield (H-1000, Vector 
Laboratories, Burlingame, CA) anti-fade mounting media and sealed with fingernail 
polish.  Negative controls were processed in parallel by omission of the primary or 
secondary antibody, and no signal was detected.  Cells were imaged, and images 
captured, using a fluorescent Nikon Microphot microscope (Nikon, Melville, NY).  
Micrographs were prepared using Adobe Photoshop (Ver. 9.0, Adobe, San Jose, 
CA) and Macromedia Freehand (Ver. 10.0, Macromedia, San Francisco, CA). 
Hydrogen Peroxide- and Glutamate-Mediated Cell Stress 
 L-glutamic acid (glutamate, 49449, Sigma), and hydrogen peroxide (H2O2, 
H325-500, Fisher), were used in these studies to induce cell stress in differentiated 
RGC-5s.  Staurosporine differentiated RGC-5s were exposed to varying 
concentrations of glutamate (50 µM - 1.4 mM), or hydrogen peroxide (10-300 µM) for 
8 hours.  Media was replaced with fresh growth media and cells grown for an 
additional 2 days.  Glutamate treated cells, and control cells, were exposed to 
buthionine sulfoximine (BSO, B2640, Sigma) following SS differentiation until the 
completion of the experiment to deplete cellular glutathione levels21, in order to make 
the cells more susceptible to glutamate induced stress.  Cells were fixed with 4% 
paraformaldehyde in 0.1 M PO4 and stained with Alexa-488 Phalloidin (5 U/ mL, 
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Molecular Probes) in order to visualize the F-actin cytoskeleton.  A naïve observer 
imaged 5 regions of each coverslip at pre-defined areas, and quantified the 
percentage of cells present on each coverslip as compared to control, vehicle 
treated RGC-5s.  The concentration at which approximately 50% of RGC-5s were 
present, as compared to controls, was used for all subsequent experiments.  Each 
experiment in these series of studies was conducted three times, with at least two 
replicates per timepoint for each experiment.  Results were analyzed statistically 
using one-way ANOVA with Bonferroni’s test for multiple comparisons.  
 
Delivering the Neuroprotective Factor BDNF to Differentiated RGC-5s 
 Genetically engineered MSCs secreting BDNF, or control cells expressing 
GFP were generated as previously described.  Engineered MSCs were plated into 
culture inserts with 0.4 µm diameter semi-permeable membranes (07-200-147, 
Fisher) in 24 well plates at a density of 452 cells/ mm2.  RGC-5s were differentiated 
as previously described in separate dishes on entactin-collagen-laminin (ECL, 10 µg/ 
mL, Chemicon) coated glass coverslips.  Following differentiation, RGC-5s were 
transferred and grown in the presence of BDNF-MSCs or GFP-MSCs for 24 hours 
directly below the insert in the lower chamber.  Following this initial period, cellular 
stressors were added to the co-cultures for 8 hours.  Media was changed to fresh 
growth media, and cells were grown for an additional 48 hours in the presence of 
engineered MSCs.  To serve as a positive control, a dose-response analysis of 
purified rhBDNF (Peprotech) was performed, based on concentrations previously 
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reported to be effective in eliciting responses from cultured RGCs29, 56.  The lowest 
concentration that had significantly more cells than glutamate or H2O2 treated RGC-
5s was placed in the media of some chambers immediately, and remained 
throughout the course of the insult.  Surviving cells were analyzed as previously 
described for each of three experiments, with at least two replicates per experiment.     
Statistical Analysis 
 All statistical analysis was performed using GraphPad Prism (Ver. 3.0, 
GraphPad Software, San Diego, CA). 
 
Results 
Staurosporine-induced differentiation of RGC-5s 
Development of in vitro systems that model RGCs and permit screening of 
potential neuroprotective compounds is paramount to developing new treatments for 
glaucoma.  We have demonstrated that naïve, undifferentiated RGC-5s have 
elongated, simple morphologies with few processes emanating from the cell body 
24-72 hours following plating (Fig. 1 A-C).  When RGC-5s were treated with SS they 
elaborated extensive processes within 24 hours following treatment, and maintained 
these complex morphologies up to 72 hours in culture (Fig 1. D-F).  While SS-treated 
RGC-5s displayed complex morphologies reminiscent of retinal neurons, we sought 
to determine if these cells were capable of expressing neuron-specific class III β-
tubulin (TuJ 1 antibody labeling), and the RGC specific transcription factor Brn3a, 
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that are expressed by RGCs in vivo.  We have demonstrated that differentiated 
RGC-5s had extensive TuJ 1 immunoreactivity (IR) in the neurites (Fig. 2 A), 
whereas RGC-5s treated with carrier solution expressed very low levels of TuJ 1-IR 
(Fig. 2 C).  Differentiated RGC-5s also expressed Brn3a in the cell soma (Fig. 2 B, 
arrows), where very low levels of Brn3a were expressed in undifferentiated RGC-5s 
(Fig. 2 D).  The proportion of RGC-5s expressing IR for each antibody was 
quantified, and it was determined that 70.26 ± 8.37% of SS- differentiated RGC-5s 
expressed TuJ 1, a significant increase from 13 ± 1.3% of control RGC-5s (Fig. 2 E, 
p < 0.0001).  In the SS differentiated RGC-5s there was also a higher incidence of 
Brn3a immunoreactive cells, with 17.36 ± 5.57% of SS treated RGC-5s expressing 
Brn3a-IR, compared to just 1.06 ± 0.82% of control RGC-5s (Fig. 2 E, p < 0.05).  
BrdU incorporation analysis was used to determine the percentage of mitotic cells in 
SS-treated vs. untreated populations of RGC-5s.  This analysis revealed 
undifferentiated RGC-5s were a highly mitotic population of cells, with 66.7 ± 1.91% 
of RGC-5s immunoreactive for anti-BrdU following a 6 hour BrdU pulse (Fig. 3 F).  
Conversely, SS-differentiated RGC-5s had significantly less BrdU uptake, with 4.62 ± 
0.76% of cells BrdU immunoreactive following differentiation (Fig. 3 F, p < 0.0001). 
These results demonstrate that not only do SS-differentiated RGC-5s have complex 
morphologies consistent with retinal neurons; they express neuronal markers 
consistent with RGCs in vivo.  Additionally, the very low percentage of mitotic cells in 
the population adds to their usefulness for use in neuroprotection experiments.  
Taken together, these results indicate that SS-treated RGC-5s undergo 
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differentiation and begin expressing markers indicitive of neuronal (RGC) 
differentiation. 
Engineering MSCs Ex Vivo 
For these series of experiments we examined the feasibility of using 
mesenchymal stem cells (MSCs) as cellular vehicles to deliver neuroprotective 
substances to compromised retinal neurons.  Mesenchymal stem cells were 
engineered to produce and secrete the neurotrophic factor BDNF using lentiviral 
vectors.  Immunocytochemical analysis of engineered cells revealed modest IR for 
BDNF in control MSCs (GFP-MSCs) in the nucleus and cell body (Fig. 3 A, B).  
Meanwhile, robust BDNF-IR was observed in the perinuclear region and cell body of 
LV-BDNF transduced MSCs (BDNF-MSCs), demonstrating the effectiveness of the 
lentiviral constructs in transducing these cells  (Fig. 3 C, D).  We examined the 
cellular localization of the high affinity BDNF receptor TrkB in control and SS 
differentiated RGC-5s to demonstrate RGC-5s express the receptor necessary for 
BDNF to elicit a response.  Control RGC-5s had diffuse TrkB-IR throught the entire 
cell (Fig. 3 E, F).  However, upon SS-differentiation RGC-5s displayed intense TrkB-
IR in the cell body (Fig. 3 G, H).   
To determine whether the secreted BDNF was bioactive, the length and 
density of neurites emanating from E17 dorsal root ganglion (DRG) cultures were 
judged by blind observers following treatment with experimental media.  Upon 
treatment with normal MSC growth media DRGs failed to elaborate extensive 
neurites (Fig. 4 A), which was also observed in DRGs exposed to GFP-MSC 
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conditioned media (CM) (Fig. 4 B, E).  No significant difference existed between 
media treated (1.87 ± 0.27) and GFP-MSC CM (1.70 ± 0.24) DRGs in terms of blind 
observer analysis of neurite length and density (Fig. 4 E, p > 0.05).  In contrast, 
DRGs that were grown in the presence of BDNF-MSC CM (Fig. 4 C) and DRGs 
treated with 100 ng of rhBDNF (Fig. 4 D) displayed extensive neurite outgrowth.  
Although DRGs treated with BDNF-MSC CM (3.02 ± 0.31), or rhBDNF (3.49 ± 0.24) 
did not differ in the amount of neurite outgrowth (Fig. 4 E, p > 0.05), these two 
treatment groups each had significantly more neurite outgrowth than DRGs treated 
with MSC media alone, or GFP-MSC CM (Fig. 4 E, p < 0.05).  These results 
demonstrate that bioactive BDNF was produced by MSCs, and that SS differentiated 
RGC-5s express the necessary receptor to mediate signals elicited by BDNF.     
Glutamate- and ROS-induced RGC-5 Loss 
We sought to determine if differentiated RGC-5s would respond to the cellular 
stressors glutamate and hydrogen peroxide, which have been implicated in RGC 
death in glaucomatous eyes.  We have shown that glutamate concentrations greater 
than 800 µM were able to induce a significant amount of RGC-5 loss, as compared 
to RGC-5s not exposed to glutamate (Fig. 5 A, p < 0.01).  For subsequent 
experiments 1 mM glutamate was used as only 56.0 ± 7.92% of RGC-5s were 
present after treatment.  In addition, we have shown H2O2 to be a potent cellular 
stressor, with concentrations greater than 10 µM inducing significant RGC-5 loss 
(Fig. 5 B, p < 0.001).  For subsequent experiments 10 µM H2O2 was used as only 
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48.90 ± 4.58% of RGC-5s were present, as compared to carrier-solution treated 
cells.  In order to determine if BDNF could prevent loss of RGC-5s following 
treatment with glutamate and H2O2, rhBDNF was applied to cultures throughout the 
stressor insult, and once after treatment.  It was determined that rhBDNF 
concentrations greater than 100 ng/ mL were able to attenuate glutamate mediated 
RGC-5 loss, protecting 87.77 ± 7.42% of RGC-5s, a significant increase from 60.60 
± 3.13% of RGC-5s present in cultures treated with glutamate only (Fig. 5 C, p < 
0.05).  We have also demonstrated that rhBDNF was able to prevent RGC-5 cell 
loss due to H2O2 at concentrations greater than 100 ng/ mL.  This application of 
rhBDNF showed 70.0 ± 14.81% of RGC-5s present, with only 48.88 ± 4.58% of cells 
present in H2O2 treated cultures (Fig. 5 D, p < 0.05).  Taken together these results 
demonstrate cell loss can be induced in RGC-5s with substances hypothesized to be 
involved in secondary degeneration of ganglion cells in glaucomatous eyes.  
Furthermore, we have demonstrated that we can attenuate RGC-5 loss by 
application of rhBDNF during the time of cellular insult.   
Delivery of BDNF to RGC-5s from Genetically Modified MSCs 
Finally, we sought to determine if BDNF released from MSCs was able to 
protect SS-differentiated RGC-5s following treatment with glutamate or H2O2.  We 
have shown that after glutamate treatment 54.0 ± 5.99% of RGC-5s remained, a 
significant decrease from non-treated RGC-5s (Fig. 6 A-C, p < 0.001).  Also, as 
previously shown, we have demonstrated significant protection, with 81 ± 3.20% of 
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RGC-5s alive after treatment with rhBDNF (Fig. 6 A, p < 0.001).  Delivery of BDNF 
from BDNF-MSCs was also able to prevent an RGC-5s cell loss, with 80 ± 5.40% of 
RGC-5s alive following glutamate treatment (Fig. 6 A, D), which was significantly 
more than the 57.29 ± 1.89% remaining in RGC-5 cultures exposed to MSCs 
transduced with only the LV-GFP vector (Fig. 6 A, E, p < 0.01).  Cellular based 
rescue experiments were also carried out using H2O2 to induce RGC-5 loss.  We 
have demonstrated again a significant decrease in remaining RGC-5s as compared 
to control cells when RGC-5s were exposed to H2O2 (Fig. 7 A-C, p < 0.001).  We 
have also shown rhBDNF, as well as BDNF-MSCs are capable of preserving RGC-
5s, with 68.67 ± 3.33% and 65.6 ± 3.47% of cells remaining, respectively (Fig. 7 A, 
D).  This was significantly greater than the 46.0 ± 4.20% of cells remaining in GFP-
MSC treated cultures (Fig. 7 A, E, p < 0.01).  Taken together these results 
demonstrate that MSCs are reliable vehicles that are capable of delivering 
neuroprotective substances to compromised cells.   
Discussion 
We have demonstrated that we can use the transformed retinal ganglion cell 
line, RGC-5s, as a model of retinal neurons by differentiating them with the general 
kinase inhibitor staurosporine.  These SS-differentiated RGC-5s develop into highly 
branched cells that morphologically resemble cultured retinal ganglion cells, 
consistent with findings presented by Frassetto et al23.  The differentiated RGC-5s 
had very low levels of BrdU incorporation, indicating cells were not proliferating.  We 
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have shown a morphological differentiation of RGC-5s from simple cells into highly 
branched, complex cells consistent with mature RGCs, as they were immunolabeled 
with the neuronal markers TuJ 1 and Brn3a following differentiation.  We have also 
shown a shift in the cellular distribution to the cell body for the high affinity BDNF 
receptor, TrkB.  The TrkB receptor is essential for correct retinal ganglion cell 
development26, 27 and survival28, 29, and we propose that the expression of this 
receptor by RGC-5s indicates these cells are assuming mature phenotypes following 
differentiation.  For the experiments presented in this body of work it was essential 
that differentiated RGC-5s closely resemble retinal ganglion cells.  Taken together, 
our results, along with previous experiments18, 23, demonstrate SS differentiated 
RGC-5s are a useful model of retinal ganglion cells.   
We investigated the potential use of the SS-differentiated RGC-5s cells as an 
in vitro model of glaucoma.  In these studies the cellular stressors glutamate and 
H2O2, which have been implicated in glaucomatous secondary degeneration of 
RGCs3-6, 9, 11, 12, were shown to induce RGC-5 cell loss, as compared to vehicle-
treated RGC-5s.  This demonstrates that RGC-5s are excellent models to investigate 
changes in retinal neurons in glaucomatous retinas.  Previous experiments have 
shown that undifferentiated RGC-5s were useful in modeling the apoptotic response 
of RGC-5s to serum deprivation19, oxidative stress20, glutamate excitotoxicity21, and 
hydrostatic pressure22.  While these early experiments have demonstrated RGC-5s 
are a useful model for RGCs, the potential for mitotic cells in the population 
confounds the results.  We have demonstrated SS-differentiated RGC-5s can serve 
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as a non-mitotic model of RGCs, that express proteins consistent with RGCs in vivo.  
Additionally, the quantity of differentiated RGC-5s present is severely diminished 
after treatment with the cellular stressors glutamate and H2O2, which have been 
implicated in the pathophysiology of advanced glaucoma.  In addition to 
susceptibility to the cellular stressors glutamate and H2O2, RGC-5s have also been 
shown to express complement proteins57, and have mitochondrial abnormalities58, 
which are each prevalent in glaucomatous eyes59, 60.  These findings make RGC-5s 
useful for evaluating delivery mechanisms, or potential neuroprotective substances 
for RGC neuroprotection in glaucomatous eyes, as many substances can be 
screened in a high-throughput manner. 
In these experiments we have demonstrated that rhBDNF can prevent SS-
differentiated RGC-5 loss mediated by glutamate and H2O2.  BDNF is an obvious 
protein to study, due to its many links to eyes with glaucomatous optic neuropathies.  
BDNF and its receptor TrkB are expressed by RGCs in the neural retina61, and 
BDNF is retrogradely transported to the retina26, 62, 63.  It has previously been shown 
that in glaucomatous eyes the retrograde transport of BDNF from the superior 
colliculus via the RGC axon is severly diminished64, 65.  We hypothesize that 
prolonged delivery of BDNF to glaucomatous eyes will prevent RGC degeneration, 
as the loss of trophic support is one cause of neurodegeneration.  The results we 
have presented here are encouraging, as BDNF is able to attenuate the loss of 
model RGCs.   
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We have demonstrated MSCs are a useful delivery system capable of 
providing neuroprotection to compromised cells by release of BDNF.  We feel that 
MSC-based delivery systems have the potential for use in clinical settings as MSCs 
are easily engineered, and can be used in an autologous fashion, which makes 
immune-mediated rejection of the transplant less likely.  Additionally, MSCs are 
easily isolated in large quantities as compared to adult CNS progenitors, and bypass 
the moral and ethical concerns typically associated with embryonic, fetal, and 
neonatal stem cell isolation.  We will continue further in vivo analysis of this delivery 
system to examine the effect of prolonged BDNF delivery in small and large animal 
models of glaucoma.   
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Figure Legends 
Figure 1. Differentiation of RGC-5s with staurosporine (SS).  Control, carrier solution 
treated RGC-5s at 24 (A), 48 (B), or 72 (C) hours after plating had simple, flat 
morphologies.  In contrast, differentiation of RGC-5s with 1 µM SS for 1 hour induced 
RGC-5s to become highly branched cells 24 (D), 48 (E), or 72 (F) hours post-
treatment. 
Figure 2.  Staurosporine differentiation upregulates neuronal marker expression in 
RGC-5s.   Differentiated RGC-5s were highly immunoreactive for the phenotypic 
neuronal marker TuJ 1 in the processes of cells (A, arrows). In addition, SS 
differentiated RGC-5s were immunoreactive for the RGC transcription factor Brn3a 
(B, arrow).  In contrast, undifferentiated, control RGC-5s expressed TuJ 1 (C, arrow) 
and Brn3a (D, arrow) at very low levels.  Quantification of the number of SS-treated 
RGC-5s expressing phenotypic markers revealed a significant increase from 13.0 ± 
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1.3 % in control RGC-5s to 70.26 ± 8.37 % in SS differentiated RGC-5s for TuJ 1 (E, 
p < 0.0001).  This trend was also observed for Brn3a expression patterns, with a 
significant increase from 1.06 ± 0.82 % of control RGC-5s expressing Brn3a to 17.36 
± 5.57 % of differentiated RGC-5s immunoreactive for Brn3a (E, p < 0.05).  Finally, 
BrdU analysis revealed differentiated RGC-5s have very low levels of BrdU 
incorporation (4.62 ± 0.76 %), a significant decrease from 66.7 ± 1.91 % of 
undifferentiated RGC-5s, (F, p < 0.0001).  
Figure 3.  In order to provide BDNF to RGC-5s for neuroprotection experiments, 
mesenchymal stem cells (MSCs) were transduced with lentiviral constructs encoding 
green fluorescent protein (GFP-MSC, A, B) or brain-derived neurotrophic factor 
(BDNF-MSC, C, D).  Transduced cells were probed with anti-BDNF antibodies.  A 
low level of BDNF was detected in the peri-nuclear region (A, arrow), and cell body 
(A, arrowhead) of GFP-MSC controls.  This control population of MSCs had high 
expression of GFP (B).  Merged image of GFP and BDNF immunoreactivity (B) 
demonstrates the cellular localization of BDNF.  In contrast to control cells, BDNF-
MSCs had increased levels of BDNF-IR in the perinuclear area (C, arrows), in 
addition to the cell body (C, arrowhead).  Merged images also revealed high levels of 
GFP expression (D), which demonstrates the localization of BDNF-IR in the cell.  
Control and differentiated RGC-5s were examined to determine if the high affinity 
BDNF receptor TrkB was present.  Undifferentiated RGC-5s had high expression of 
TrkB in the perinuclear region (E, arrows), and in distal parts of the cell (E, 
arrowhead).  TrkB immunoreactivity (IR), merged with the Alexa-488 phalloidin 
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stained cytoskeleton demonstrates the cellular localization of TrkB (F).  
Differentiated RGC-5s displayed localized TrkB-IR in the cell body (G, arrow), as 
compared to undifferentiated RGC-5s.  Merged image (H) demonstrates cellular 
localization of TrkB in differentiated RGC-5s. 
Figure 4.  BDNF produced by engineered MSCs was verified as bioactive, based on 
neurite outgrowth and density from embryonic dorsal root ganglia (DRG) cultures.  
When cultured with standard MSC growth media DRGs elaborated few neurite 
processes (A).  Likewise, GFP-MSC conditioned media (CM) did not induce 
significant neurite outgrowth (B).  However, when DRGs were cultured in either 
BDNF-MSC CM (C), or media containing rhBDNF (D), significant neurite outgrowth 
was observed.  Blind observer analysis (E) revealed no significant difference in the 
amount or density of neurite outgrowth in DRGs grown in media, or GFP-MSC 
conditioned media (p > 0.05).  No significant difference was observed in DRGs 
treated with BDNF-MSC CM, or rhBDNF.  However, significantly more neurite 
outgrowth in DRGs treated with BDNF-MSC CM or rhBDNF was observed when 
compared to DRGs grown in either GFP-MSC CM or media alone (p < 0.05).   
Figure 5.  Differentiated RGC-5s are susceptible to glutamate and H2O2 induced cell 
loss, and can be prevented with rhBDNF.  Significant cell loss can be induced in SS 
differentiated RGC-5s with glutamate treatment at concentrations greater than 800 
µM, as compared to vehicle treated control RGC-5s (A, p < 0.05).  H2O2 also proved 
to be a potent inducer of significant cell loss at concentrations of 10 µM and greater 
(B, p < 0.05).  Cell loss induced by glutamate (C), or H2O2 (D) could be attenuated by 
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addition of rhBDNF concentrations at 100 ng/ mL and greater (p < 0.05), as 
compared to RGC-5s treated with glutamate or H2O2 only.   
Figure 6. BDNF released from MSCs can protect RGC-5s from glutamate mediated 
RGC-5 loss.  Following treatment with 1 mM glutamate, only 57.29 ± 1.89 % of RGC-
5s remained.  When glutamate treated RGC-5s were grown in the presence of 
BDNF-MSCs or rhBDNF, a significant amount of cells were present, compared to 
cultures not exposed to BDNF (A, p < 0.05).  We have demonstrated GFP-MSCs 
were not able to prevent RGC-5 cell loss following glutamate treatment.  
Representative images are shown for control RGC-5s (B), RGC-5s exposed to 1 mM 
glutamate (C), and RGC-5s exposed to 1 mM glutamate and grown in the presence 
of BDNF-MSCs (D) or GFP-MSCs (E).    
Figure 7. BDNF released from MSCs can protect RGC-5s from H2O2 mediated cell 
loss.  Following treatment with 10 µM H2O2, only 44.5 ± 2.2 % of RGC-5s were 
present, as compared to vehicle-only treated cultures (A).  When H2O2 treated RGC-
5s were grown in the presence of BDNF-MSCs or rhBDNF, a significant amount of 
cells were present, as compared to RGC-5s grown in the presence of GFP-MSCs (p 
< 0.001). We have demonstrated less RGC-5s present when grown in the presence 
of GFP-MSCs, as compared to vehicle and BDNF-exposed cells.  Representative 
images are shown for control RGC-5s (B), RGC-5s exposed to 10 µM H2O2 (C), and 
RGC-5s exposed to H2O2 and grown in the presence of BDNF-MSCs (D) or GFP-
MSCs (E). 
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Abstract 
 Glaucoma refers to a family of optic neuropathies that lead to retinal ganglion 
cell death, optic nerve degeneration, and subsequent blindness if left untreated.  
Many factors contribute to the death of RGCs in glaucoma, including a decreased 
retrograde transport of the neurotrophin BDNF from target structures in the brain.  In 
this study we have engineered mesenchymal stem cells (MSC) with lentiviral vectors 
to produce and secrete bioactive BDNF.  We subsequently used these cellular 
vehicles to deliver BDNF to glaucomatous rat eyes.  We have shown that BDNF 
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delivery to hypertensive eyes is capable of preserving visual function, as assessed 
using eletroretinography and computerized pupilometry.  In addition, we have shown 
a robust preservation of retinal and optic nerve architecture, as compared to control 
eyes injected with GFP-expressing MSCs.  Taken together, these results 
demonstrate MSCs are useful vehicles to deliver neuroprotective substances to 
diseased retinas.   
Introduction 
Glaucoma is a family of ocular neuropathies that lead to retinal ganglion cell 
(RGC) death, optic nerve degeneration, and subsequent blindness if left untreated1. 
While the initial causes for the onset of glaucoma have not been elucidated, many 
factors that contribute to the neurodegeneration of RGCs have been identified, 
including; changes in glia of the optic nerve head2, a decrease in retrograde 
transport of vital trophic factors3, 4, glutamate-mediated excitotoxicity5, 6, oxidative 
stress mediated via reactive oxygen species (ROS)7-9, and involvement of the 
immune system10, 11, among others.   Glaucoma accounts for a significant portion of 
all blinding diseases, and it is projected that there will be 61 million cases of 
glaucoma worldwide by 2010, with 8.5 million of these people becoming bilaterally 
blind12.  There are currently no treatments that provide protection to RGCs from 
primary or secondary degeneration.  In these series of experiments we will describe 
a cellular-based therapy for protection of retinal neurons in a rodent model of 
glaucoma. 
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  While the etiology that contributes to RGC degeneration in glaucomatous 
optic neuropathies has not been identified, we are able to recapitulate many aspects 
of the human disease using reliable, reproducible models of glaucoma.  In our 
studies we use the rat chronic ocular hypertension (COH) model of glaucoma as 
previously described13.  This, and other models of glaucoma result in decreased 
retinal and optic nerve function13, 14, RGC death13, 15-17 mediated via apoptosis15, 17, 
and subsequent optic nerve degeneration.  The COH model also mimics human 
glaucoma in the fact that the increased IOP can be controlled with drugs currently 
used to clinically treat glaucoma18.  This inducible and reproducible model is 
desirable for use in neuroprotection experiments, as the onset of degeneration is the 
same in each animal.  This is essential so that comparisons at specific timepoints 
may be directly made between treatment groups.   
 A significant effort has been made to develop cell-based therapies to treat 
retinal disease using a variety of cells derived from distinct tissues.  Cells that have 
been identified as potentially useful for these types of therapies include: embryonic 
stem cells19, retinal progenitor and precursor cells20-23, neural progenitor cells20, 24-29, 
Schwann cells30-33, fibroblasts31, retinal pigment epithelium34, 35, limbal and 
conjunctival epithelial stem cells36, and sheets of retinal derived tissue37, 38.  While 
interesting results have been obtained using these experimental approaches, they 
suffer from drawbacks that make them less than ideal for clinical applications, 
including the generation of a sufficient quantity of cells for transplant, and immune 
compatibility with the host.  Additionally, cells derived from embryonic, fetal, neonatal 
 97 
tissue raise major moral and ethical concerns, as well as have the potential to harm 
the host39.  We propose an alternative cell type, mesenchymal stem cells (MSCs), to 
be used as cellular vehicles for the treatment of retinal disease. 
We believe that MSCs are excellent sources of stem cells for CNS-directed 
cell-based therapies due to their plasticity40, and ease of isolation and expansion41, 42.  
Several groups have demonstrated the plasticity of this population of cells by 
showing that MSCs were able to differentiate into neural-like cells43-47 in vitro, some 
of which displayed electrophysiological properties consistent with mature CNS 
neurons45, 47.  For cell-based therapies to be effective, it is essential that the 
transplanted cells are able to thrive in the host environment.  Previous studies have 
shown MSCs have the capacity to survive, migrate, and integrate into CNS 
environments following transplantation46, 48-51.  Furthermore, naïve, unmodified, MSCs 
have been shown to have neuroprotective effects when transplanted into mouse 
models of retinal degeneration52-54.  Due to MSCs rapid expansion and ease of use it 
is conceivable to use them in an autologous fashion, in which cells are isolated from 
a patient, genetically modified, and transplanted back into the same host.  These 
strategies are attractive, as immune rejection of transplanted material becomes less 
of an issue, as well as bypassing moral and ethical objections to using embryonic, 
fetal, and neonatal derived stem cells.  For these reasons we propose that MSCs are 
ideal to use as cellular vehicles to deliver neuroprotective substances to diseased 
retinas. 
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In order to preserve retinal function and architecture in these experiments, 
brain-derived neurotrophic factor (BDNF) was used, as it has been identified as 
having the capacity for neuroprotection.  The neurotrophin BDNF is produced as a 
pre-pro-neurotrophin that is cleaved to the 14 kD mature form55 which preferentially 
binds to its high affinity receptor, TrkB56.  Target-derived BDNF is essential for 
correct RGC development57-59 and is also important for ex vivo maintenance of 
RGCs60, 61.  It has been shown that retrograde transport of target-derived BDNF to 
the retina is severely decreased in models of glaucoma4.  In previous experiments, 
bolus injections of BDNF into these models have shown to be neuroprotective for 
retinal neurons, based on morphometric analysis of the tissue62-68.  Additionally, 
BDNF delivery via viral vector has proven to be effective in attenuating cell death in 
models of retinal disease69, 70.  While these results are very encouraging from a 
basic-sciences point of view, these delivery methods of BDNF to eyes with chronic 
ocular diseases are not viable in a clinical setting.  We demonstrate a minimally 
invasive, cell-based therapy that is capable of providing neuroprotection to retinal 
neurons via BDNF delivery in the COH rat model of glaucoma. 
In this study we have demonstrated MSCs are excellent cellular vehicles for 
treatment of neurodegenerative diseases, as they can be efficiently engineered to 
secrete bioactive BDNF.  Furthermore, we have demonstrated that MSC delivery of 
BDNF into chronic ocular hypertensive eyes results in neuroprotection of retinal 
function, as assessed by the non-invasive measures of retinal and optic nerve 
function, electroretinography and computerized pupilometry, respectively.  Rigorous 
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histological analysis of retinal tissue revealed significant preservation of RGC and of 
retinal architecture, as well as increased optic nerve integrity in BDNF treated eyes, 
as compared to control eyes.  These results represent a significant advance in the 
field of stem cell-based neuroprotection of chronic neurodegenerative diseases, and 
pave the way toward validating these therapeutic approaches in large animal models 
that faithfully recapitulate the pathophysiology of human glaucoma over a prolonged 
period of time.    
Materials and Methods 
Rat Mesenchymal Stem Cells  
Rat MSCs (Tulane Center for Gene Therapy, New Orleans, LA) were 
maintained as an adherent cell line in ∝-MEM media (12561-049, Invitrogen) 
containing 20% hybridoma qualified fetal bovine serum (FBS, S11595, Atlanta 
Biologicals, Norcross, GA), 2 mM L-glutamine, and antibiotic-antimycotic (1%,15240-
096, Invitrogen; 10,000 U/mL penicillin, 10,000 µg/mL streptomycin, 25 ng/mL 
amphotericin B).  Cells were maintained as low-density cultures at 75-150 cells/ cm2.  
When cultures reached 70-80% confluency MSCs were gently lifted from the dish 
using 0.25% trypsin-0.1% EDTA solution (Invitrogen).  Fresh media was added to 
inactivate the trypsin, and MSCs were pelleted at 800g.  MSCs were subsequently 
plated into 150 mm culture dishes at 75-150 cells/ cm2.  Cultures were fed by 
supplementing the dish with fresh media every other day.   
 100 
Engineering Stem Cells Ex-Vivo with Lentiviral Vectors 
Mesenchymal stem cells were engineered to produce and secrete the 
neurotrophic factor BDNF using lentiviral vectors.  Briefly, MSCs were plated in 6 
well plates at a density of 1000-1200 cells per well and allowed to adhere for 12 
hours.  After adhering to the plate, the growth media was substituted in each well 
with α-MEM containing 2% FBS and 12 µg/ml sequabrene (152667, Sigma).  Two 
separate lentiviral vectors encoding 1) BDNF (LV-BDNF) and 2) green fluorescent 
protein (GFP, LV-GFP) were added simultaneously to MSCs at a multiplicity of 
infection (MOI) of 15 for each construct.  A population of control MSCs was 
engineered with the LV-GFP vector, only, at an MOI of 30 to match the viral titer 
added to the BDNF/GFP engineered MSCs.  Viral particles were removed after 8 
hours of exposure, and media was changed to fresh growth media.  Engineered 
MSCs were subsequently maintained as previously described. 
ELISA 
Enzyme-Linked-Immuno-Sorbent-Assay (ELISA) was used to quantify the 
amount of BDNF released from BDNF-MSCs and GFP-MSCs, respectively.  The 
BDNF EMax Immunoassay System (G7610, Promega Corporation, Place) was used to 
detect BDNF in media conditioned for 24 hours by BDNF-MSCs and GFP-MSCs.  
Initially, 350,000 cells were plated into 150 mm2 plates and allowed to adhere for 24 
hours.  Media was replaced with fresh growth media, and cells were grown for an 
additional 24 hours.  Media was collected and frozen at -20°C for subsequent 
analysis.  The presence of BDNF in the conditioned media (CM) was analyzed as 
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follows.  Briefly, Anti-BDNF mAb in carbonate buffer was used to coat the wells of a 
96 well plate overnight at 4°C.  Wells were incubated with sample buffer and blocker 
for 1 hour at room temperature.  Samples from CM and a purified BDNF standard 
curve (0-500pg/ well) were prepared and incubated in wells on a shaker for 2 hours.  
Wells were subsequently washed, an anti-BDNF pAb was added to the wells, and 
plates were incubated again on a shaker for 2 hours.  An anti-IgY HRP conjugated 
antibody was incubated in the wells on a shaker for 1 hour at room temperature and 
subsequently washed.  100 µL of TMB-One solution was added to each well and 
reacted for 10 minutes at room temperature.  Reactions were stopped by addition of 
100 µL of 1 N HCl per well.  Plates were read using an EL800 Universal Microplate 
Reader at 450nm (BioTek Instruments, Winooski, VT), and data was analyzed with 
KC Junior Software (BioTek Instruments). 
Neurotrophin Bioactivity Assay 
 All animal studies were conducted in accordance with the ARVO Statement 
for the Use of Animals in Ophthalmic and Vision Research, and had approval of the 
Iowa State University Committee on Animal Care.  Primary cultures of rat embryonic 
day 17 (E17) dorsal root ganglia (DRG) were used to assess the bioactivity of BDNF 
released from MSCs, as DRGs have been shown to elongate neurites in response to 
neurotrophin exposure71, 72.  Briefly, E17 rat pups were decapitated, rinsed in ice-cold 
70% ethanol, and subsequently placed in ice-cold DMEM.  Spinal columns were 
dissected via a ventral approach in ice-cold L-15 media (21683-027, Invitrogen), 
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lumbar DRGs were dissected, and subsequently pooled.  Following dissection, 
DRGs were rinsed with ice-cold L15 and transferred to warm DRG growth media 
containing DMEM, L-glutamine, penicillin-streptomycin, and 10% FBS.  Three to four 
DRG explants were transferred in approximately 75 µL of media onto poly-L-
ornithine coated coverglass placed in 24 well culture plates.  DRGs were allowed to 
adhere for 8 hours, and wells were flooded with experimental media.  The 
experimental media that DRGs were grown in included MSC growth media, MSC 
media conditioned by BDNF-MSCs or GFP-MSCs, respectively, or MSC media 
containing 50 ng recombinant human BDNF (rhBDNF, 450-02, Peprotech, Rocky 
Hill, NJ).  Explants were allowed to grow for an additional 48 hours, and 
subsequently fixed with 4% paraformaldehyde in 0.1M PO4 buffer (pH 7.4).  To 
visualize and quantify neurite outgrowth, cultures were stained with an anti-
neurofilament antibody (RMO.308, 1:50, Virginia Lee, University of Pennsylvania), 
as described below. Montage images were presented to seven naïve observers in 
order to judge the extent and density of neurite outgrowth in each condition.  Each 
DRG was scored on a scale from 1-5; with 1 representing modest neurite growth in 
terms of length and density, and 5 representing long, dense neurite arborization from 
the DRG.  Data from this analysis was pooled and statistical analysis was 
performed. 
Laser Induced Chronic Ocular Hypertension 
Rat COH models of glaucoma were created as previously described by 
Grozdanic and colleagues73.  Briefly, to induce obstruction of the aqueous humor 
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outflow, Indocyanine green (10 µl; 10 mg/ ml, Sigma) was injected into the anterior 
chamber of the eye in 24 adult Brown Norway retired breeder male rats.  Animals 
were pretreated with 4% pilocarpine hydrochloride eye drops to localize the dye to 
the trabecular meshwork and episcleral veins.  Twenty minutes post injection, a 
diode laser (DioVet, Iridex Corporation, Mountian View, CA) was used to deliver 810 
nm energy pulses through a 50 µm fiberoptic probe to the region of the trabecular 
meshwork and episcleral veins in order to cauterize the aqueous humor outflow of 
the eye.  Approximately 50-60 laser spots through a 300° range of the limbal radius 
(350 mW energy, 1500 ms pulse time) were used to achieve this objective.  Rats 
were given acetaminophen (100 mg/kg) and codeine (75 mg/kg) in the drinking 
water for 7 days following induction to control pain.  Antibiotic ointment was applied 
to the cornea to prevent infection. 
Cell Transplantation 
MSCs were engineered and amplified as previously described.  Two days 
following aqueous humor obstruction, a small hole was punched in a dorso-lateral 
location in the eye with a 30G needle.  A beveled glass microelectrode attached to a 
hamilton syringe was inserted in this opening, and 200-300,000 cells were delivered 
intra-vitreally in approximately 1.5-2 µL of EBSS.  The electrode was allowed to 
remain in the eye for a few moments until all cells were deposited in the vitreous.  A 
small amount of antibiotic ointment was applied to the cornea, and eyelids were 
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sutured shut to prevent the animals from scratching the cornea until the first 
recording session.   
Electroretinogram 
Rats were dark adapted for at least 12 hours prior to recording, and 
anesthetized with 3.5% halothane, 30% NO, and 70% O2 until animals were 
unresponsive to the righting reflex.  Animals were subsequently maintained using 
1.5% halothane, 30% NO, and 70% O2.  Eyes were dilated using 1% tropicamide 
and 2.5% phenylephrine.  Animals were positioned on a heating pad to maintain 
body temperature on a sliding stage under dim red illumination.  Ground and 
reference electrodes were placed subcutaneously in the tail and forehead of the 
animal, respectively.  A solid recording electrode was placed on each eye in contact 
with the cornea using a thin layer of methylcellulose to decrease the recording noise.  
Following placement of the electrodes, animals were dark adapted again for 30 
minutes prior to recording.  An automated electroretinogram (ERG) protocol (ISCEV-
ERG) was used to evaluate the electroretinographic parameters.  Scotopic rod 
responses (0.22 cd/m2, 1-300Hz, avg. 8) were collected, followed by: scotopic 
maximum combined response (78 cd/m2, 1-300 Hz, avg. 8), oscillatory potentials (78 
cd/m2, 1-300 Hz, avg. 8), photopic cone response (21 cd/m2 rod bleaching flash 
followed by 78 cd/m2 stimulation, 1-300 Hz, avg. 8), and flicker ERG (78 cd/m2, 1-300 
Hz, avg. 50).  ERGs were subsequently analyzed using the RETIport32 software 
(Roland Instruments, Wiesbaden, Germany). 
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Computerized Pupilometry 
Computerized pupillometry was used to assess the consensual pupillary light 
reflex (PLR) from eyes pre-induction, as well as 10, 25, and 42 days post-induction.  
Animals were anesthetized using 3.5% halothane, 30% NO, and 70% O2.  Once 
animals had lost the righting reflex, they were maintained with 1% halothane, 30% 
NO, and 70% O2.  Animals were positioned under a two-channel pupilometer 
(Neuroptics, San Clemente, CA) containing cameras focused on each eye with LED 
diodes alternately stimulating the control (non-operated) or experimental (operated) 
eye.  Five light intensities were used to assess the PLR, with three stimuli per 
intensity for each eye.  The initial stimulation intensity for pupilometry was 78 cd/m2, 
which was reduced 50% each time for light stimuli of 31, 18, 8.2, and 4 cd/m2.  Data 
collected from these stimuli was used to obtain a mean response for each light 
intensity.  This data was then pooled with other animals for statistical analysis using 
Students t-test.  Six separate parameters were simultaneously measured at each 
light intensity for these experiments.  These parameters included: change in pupil 
area (µm), change in pupil diameter (µm), pupil constriction and dilation velocities 
(m/s), as well as pupil constriction and dilation latencies (m/s).   
Tonometry 
Modified Goldman applanation tonometry was used to monitor the intraocular 
pressure (IOP) in experimental and control eyes.  Animals were quickly handled and 
maintained on a very light plane of anesthesia so as not to affect the IOP74.  
Flourescein was added to each eye, and a prism was used to monitor the IOP of 
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each eye at 10, 25, and 42 days post-operatively.  Three measurements were taken 
from each eye, and all measurements were used to calculate the average IOP 
reported here.  Animals that did not develop increased IOP, or had ulcerated or 
otherwise severely damaged corneas were excluded from the study.  Five animals in 
the BDNF-MSC group, and six animals in the GFP-MSC group were removed from 
the study.   
Tissue Preparation 
Rats were deeply anesthetized with halothane and quickly decapitated.  Eyes 
were dissected and drop fixed in 4% paraformaldehyde (pH 7.4).  Optic nerves were 
dissected from the eye prior to fixation and drop fixed in a combination of 2% 
paraformaldehyde/ 2% gluteraldehyde.  Eye tissue was embedded in OCT and cut in 
15-19 µM sections on a cryostat for subsequent analysis.       
Optic Nerve Quantification 
 Optic nerves were quantified using a semi-quantitative method that assesses 
optic nerve integrity. Briefly, two individuals blinded to the treatment received by 
each animal scored optic nerves independently on a scale of 1 to 5, with 1 
representing healthy optic nerves.  This scoring system is based on the overall 
appearance of the optic nerve, which includes observation of broken or missing 
axons, and observation of astrocytes that indicate damage to the optic nerve.  Data 
was pooled and analyzed using unpaired t-tests.   
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Retinal Architecture Analysis 
Hematoxylin and eosin staining was used to stain retinal layers for use in 
morphometric analysis.  Briefly, cryosectioned slides were rehydrated in ddH20 for 
one minute and stained in Harris hematoxylin for 3 minutes.  Slides were 
subsequently rinsed in running tap water for four minutes and dipped 5 times in acid 
alcohol (1% conc HCl in 70% EtOH).  Nuclei were stained using Scots Water (1L 
ddH20, 10 g MgSO4, 2 g NaHCO3) for 2 minutes.  Slides were rinsed in 70 and 80% 
EtOH for 1 minute each, and incubated in Eosin Phloxine-B (2% Eosin Y + 1% 
Phloxine-B in 95% EtOH) for 1.5 minutes.  Slides were rinsed three times in 95 and 
100% EtOH for 30 seconds and 1.5 minutes, respectively.  Finally slides were 
cleared in xylene and mounted using Cytoseal (4821-2154, VWR, Bridgeport, NJ).    
 Four images of H/E stained tissue were taken from each animal in central and 
peripheral locations in the retina at the same magnification, and sized to the same 
dimensions in Photoshop (Adobe).  A scale bar taken at the same magnification was 
manipulated in the same way in order to calibrate the software.  Images were 
imported into ImageJ (NIH), and 10-15 measurements were taken of each retinal 
layer on each image to measure the outer nuclear layer (ONL), outer plexiform layer 
(OPL), inner nuclear layer (INL), inner plexiform layer (IPL), and the total thickness 
of the retina, spanning the width from the outermost portion of the outer nuclear layer 
to the innermost portion of the ganglion cell layer.  These measurements were then 
pooled, and averaged to yield one measurement per retinal layer for each eye.  Data 
was compiled for each group, and analyzed using the unpaired t-test.     
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Immunohistochemical Analysis of Tissue Sections 
Immunohistochemical procedures were used to detect antigens expressed by 
specific cell types in the neural retina.  Briefly, cryosections were re-hydrated in 
KPBS and incubated in blocking solution containing 0.1% bovine serum albumin 
(BSA, A9647, Sigma), and 0.04% Triton X-100 (Fisher), and 5% normal donkey 
serum (NDS, 017-000-121, Jackson ImmunoResearch, West grove, PA).  Primary 
antibodies (Table 1) were diluted in blocker and incubated overnight at room 
temperature.  Tissue was rinsed with KPBS containing Triton-X, and incubated with 
Cy-3 conjugated secondary antibodies for 2 hours.  Following rinses, 4’, 6’-
diamidino-2-phenylindole, dilactate (DAPI, 1 µg/ mL, D3571, Sigma) was applied for 
30 min at room temperature in order to visualize nuclei.  Slides were mounted with 
Gelmount anti-fade mounting media and sealed.  Negative controls were processed 
in parallel by omission of the primary or secondary antibody.  Tissue was imaged 
using a Nikon Microphot microscope (Nikon, Melville, NY).  Micrographs were 
prepared using Adobe Photoshop (Ver. 9.0, Adobe, San Jose, CA) and Macromedia 
Freehand (Ver. 10.0, Macromedia, San Francisco, CA). 
Statistical Analysis 
 Statistical analysis was performed using Students t-test with Graphpad Prism 
(Ver. 3 GraphPad, San Diego, CA). 
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Results 
Engineering MSCs to Secrete BDNF 
Lentiviral vectors were used to engineer MSCs to produce the neurotrophic 
factor BDNF or GFP.  We have shown MSCs transduced with LV-BDNF constructs 
displayed intense anti-BDNF immunoreactivity (IR) in the perinucler area within the 
cell body (Fig. 1 A).  To ensure that the intense IR was due to transduction by a viral 
construct, anti-GFP antibodies were used to identity GFP produced by the IRES-
GFP site, and to examine the cellular localization of BDNF immunoreactivity (Fig. 1 
B, C).  In contrast, MSCs transduced with LV-GFP vectors displayed less intense 
BDNF-IR as compared to BDNF-MSCs, but expressed high levels of GFP (Fig. 1 D-
F), suggesting BDNF upregulation in MSCs is due to BDNF gene delivery, not an 
artifact of general lentiviral transduction. 
To determine if transduced MSCs were capable of secreting BDNF, ELISA 
analysis of the media conditioned by engineered MSCs was performed.  Secretion of 
BDNF from control GFP-MSCs was 0.97 ± 0.52 ng BDNF/ mL/ 106 cells / day, and 
was significantly less than the 41.40 ± 1.32 ng/ ml/ 106 cells/ day secreted by BDNF-
MSCs (Fig. 2 A, B; p < 0.0001).  Rat embryonic DRG cultures were used to 
investigate the bioactivity of the secreted BDNF.  The length and density of neurites 
extending from DRGs cultured in control media, or media conditioned by engineered 
MSCs was assessed by blind observers and quantified.  Upon treatment with media 
only, DRGs elaborated relatively short neurites (Fig. 2 C).  A similar level of modest 
outgrowth was observed in DRGs treated with GFP-MSC CM (Fig. 2 D), and 
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statistical analysis revealed no significant difference between these two groups (Fig. 
2 B, p > 0.05).  In contrast, DRGs that were treated with BDNF-MSC CM (Fig. 2 E) 
and DRGs treated with 50 ng of rhBDNF (Fig. 3 F) displayed extensive neurite 
outgrowth, and often elaborated processes in excess of 1.6 mm from the explant.  
Although DRGs treated with BDNF-MSC CM, or rhBDNF did not differ in the extent 
of neurite outgrowth as compared to each other (p > 0.05), these two treatment 
groups each had significantly greater outgrowth scores than DRGs treated with 
media, or GFP-MSC CM (Fig. 3 B, p < 0.05).  Taken together, these results 
demonstrate that baseline production of BDNF by GFP-MSCs is very low, and 
possessed little neurite outgrowth promoting activity.  We have demonstrated a 
significant increase in BDNF production by MSCs by engineering them with lentiviral 
vectors.  Furthermore, we have demonstrated that this transduction results in 
secretion of bioactive BDNF.  
Rat Chronic Ocular Hypertension Model of Glaucoma 
In these studies we used the rat chronic ocular hypertension (COH) model of 
glaucoma.  This is a valuable model of glaucoma, as the increased intraocular 
pressure (IOP) mimics the pathophysiology of human glaucoma.  Baseline 
measurements of IOP for eyes of BDNF-MSC and GFP-MSC animals prior to COH 
induction, or transplant, were 15.86 ± 0.77 and 14.33 ± 0.84 mmHg, respectively, 
which was not significantly different between groups (Fig. 3 A, p > 0.05).  Following 
induction of COH by cauterization of aqueous humor outflow, a significant increase 
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in IOP was observed (Fig. 3).  The IOP for BDNF-MSC and GFP-MSC treated eyes 
10 days post induction was 21.36 ± 1.34 and 20.83 ± 1.20 mmHg, respectively, and 
was not significantly different between groups (Fig 3 A, p > 0.05).  These increased 
IOP values, however, were significantly different than fellow, control eyes which had 
IOPs of 11.79 ± 0.74 for BDNF-MSC fellow eyes, and 12.33 ± 0.81 for GFP-MSC 
fellow eyes (Fig. 3 A, p < 0.0001).  The increased IOP in operated eyes was also 
apparent 25 days post-induction, with the IOP for BDNF-MSC (18.14 ± 0.80 mmHg) 
and GFP-MSC (19.58 ± 1.8 mmHg) treated COH eyes significantly greater than 
control fellow eyes (12.86 ± 0.70 and 13.33 ± 0.71 mmHg, respectively, Fig. 3 A, p > 
0.05).  The increased IOP returned to near baseline levels by 42 days post-
induction, with IOPs of 15.17 ± 1.0 and 14.75 ± 0.83 mmHg for BDNF-MSC and 
GFP-MSC treated groups, and were not significantly different from each other (Fig. 3 
A, p > 0.05).  Additionally, these values were not significantly different from fellow 
eyes for BDNF-MSC (12.83 ± 0.47 mmHg) or GFP-MSC (12.42 ± 0.61 mmHg) 
treated animals (Fig. 3 A, p > 0.05).  To ensure there was no significant difference in 
the relative change in IOP between BDNF-MSC and GFP-MSC treated animals, we 
subtracted the fellow IOP from the experimental eye IOP (Δ IOP, Suppl. Table 1) and 
subjected these values to statistical analysis.  This analysis revealed no significant 
difference in the Δ IOP at any timepoint (Fig. 3 B, p > 0.05).  This demonstrates 
functional and anatomical deficits observed in subsequent analysis are not due to 
variation of IOP between groups.  Taken together these results confirm the increase 
in IOP in our models of COH, as previously described73. 
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Analysis of Retinal and Optic Nerve Function 
 Retinal function was assessed using electroretinogram (ERG) recordings and 
computerized pupilometry, which revealed robust preservation of retinal function in 
BDNF-MSC treated animals.  In the ERG analysis we have examined evoked 
responses from rods, cones, maximum combined rod and cone responses, 
oscillatory potentials, and flicker ERG.  The maximum combined response from 
BDNF-MSC treated eyes was significantly greater, as compared to GFP-MSC 
treated eyes at 40 days post-op (Fig. 4 A-C).  This was also the case with oscillatory 
potentials, which represent functional connections between RGCs and inner retinal 
neurons (Fig. 4 D-F).  Additionally, inner retinal function driven by cones revealed 
significantly larger amplitudes in BDNF-MSC treated eyes as compared to GFP-MSC 
treated eyes (Fig. 4 G-I).  We have compiled representative ERG traces from fellow 
and hypertensive BDNF-MSC and GFP-MSC treated eyes at 20 (Suppl. Figs. 1, 2, 
respectively) and 40 days post-op (Suppl. Figs. 3, 4) for all stimulation protocols.  
Analysis of ERG responses revealed no significant difference in the amplitude of 
responses when the fellow eyes of the BDNF-MSC and GFP-MSC transplanted 
groups were compared, indicating that ERG analysis was uniform for each group 
(Suppl. Table 2).  There were, however, significant differences in the amplitude of 
multiple parameters when BDNF-MSC and GFP-MSC treated hypertensive eyes 
were examined (Suppl Table 2).  Ratios of experimental eye ERG responses 
compared to those of fellow eyes are presented here for clarity (Table 2).  Finally the 
latency of responses was examined, and no differences were found between eyes, 
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with the exception of rod b-wave latencies at 40 days post-op in experimental eyes 
(Suppl. Table 3), again confirming stimulation protocols were the same for each 
group.     
 Computerized pupillometry was used to assess optic nerve function using the 
pupillary light reflex.  For these studies we assessed parameters associated with 
pupillary constriction in the control right eye mediated by direct (stimulation to the 
right eye), or indirect (stimulation to the left eye) stimuli, and presented these as 
ratios of indirect/direct responses.  We present data from 42 days following 
transplant for simplicity.  We have demonstrated a significantly increased response 
ratio in the change in pupil area at 78 cd/m2 (Fig. 5 A), but not at lower light 
intensities 42 days after transplant.  A similar pattern as pupil area was observed in 
the pupil diameter analysis, although the two groups were not significantly different 
(Fig. 5 B).  We have demonstrated BDNF-MSC mediated neuroprotection of pupil 
constriction velocity and latency at 18 cd/m2 illumination (Fig 5 C, D).  Lastly, BDNF-
MSC treated animals had significantly better pupil dilation velocity responses at 31 
and 8.2 cd/ m2 than GFP-MSC treated animals (Fig. 5 E).  Pupil dilation latencies for 
each group were not significantly different (Fig. 5 F).  In conclusion, these results 
represent robust neuroprotection of retinal and optic nerve function mediated by 
BDNF-MSCs, but not GFP-MSCs, a substantial period after transplantation. 
MSCs can survive in hypertensive eyes 
 Examination of experimental groups after tissue was prepared for analysis 
revealed MSCs were capable of surviving in hypertensive eyes using an anti-GFP 
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antibody to detect engineered MSCs.  Transplanted MSCs were predominantly 
found adjacent to the GCL in intact retinas (Fig. 6 A-C).  In contrast, transplanted 
MSCs readily integrate into neural retinas with disrupted architecture (Fig. 6 D-F).  In 
addition, MSCs were found in the vitreous of the eye (Suppl. Fig. 5 A-C), in the optic 
nerve head region (Suppl. Fig. 5 D-F), and in retinal periphery (Suppl. Fig. 5 G-I).  
These results demonstrate that MSCs are able to survive in hypertensive eyes with 
relatively normal architecture, or with disrupted retinal architecture.  These results 
are extremely encouraging for using MSCs as vehicles to deliver neuroprotective 
substances, as they can survive for at least 6 weeks following transplant into COH 
eyes.   
Retinal Ganglion Cell and Optic Nerve Quantification 
 Retinal ganglion cells were identified based on immunoreactivity for the RGC 
specific transcription factor Brn3a, and were counted to determine the level of 
neuroprotection provided to RGCs from BDNF-MSCs.  Analysis of baseline 
measurements for Brn-3a-IR RGCs in the GCL in fellow eyes for BDNF-MSC and 
GFP-MSC treated rats revealed no significant difference between groups, with 355.4 
± 31.20 and 362.9 ± 36.47 RGCs per section, respectively, (Fig. 7 A, B, G; p > 0.05).  
However, quantification of Brn3a-IR RGCs in BDNF-MSC treated eyes revealed a 
significant neuroprotection of RGCs as compared to GFP-MSC treated eyes with 
175.1 ± 28.16, and 74.0 ± 21.53 RGCs per section, respectively (Fig. 7 C-G, p > 
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0.05).  Analysis revealed both groups had significantly less RGCs than control fellow 
eyes (Fig. 7 G, p < 0.05).   
Optic nerve (ON) integrity was also examined to compare the ONs from the 
untreated, control eye to the ONs from BDNF-MSC and GFP-MSC treated animals.  
Blind observer analysis revealed no significant difference in the appearance of optic 
nerves from BDNF-MSC eyes (2.4 ± 0.40, Fig. 8 A) and the fellow control eyes (1.4 
± 0.25, Fig. 8 B, E, p > 0.05).  In contrast, there was a significant difference in ON 
integrity when comparing optic nerves from GFP-MSC treated eyes (3.6 ± 0.75, Fig. 
8 C), and the ONs from their fellow controls (1.0 ± 0.0, Fig. 8 D, E, p < 0.05).  Taken 
together, these results demonstrate BDNF is capable of preserving RGCs and their 
axons in COH eyes.   
Morphometric and Phenotypic Analysis of Retinal Architecture 
Following analysis of RGCs and their axons in the optic nerve, we sought to 
determine if BDNF-MSCs were capable of preserving other retinal neurons from 
secondary retinal degeneration.  This was accomplished by quantitative assessment 
of retinal layer thickness from H/E stained retinal sections comparing control fellow 
eyes of each group, eyes treated with BDNF-MSCs, and eyes treated with GFP-
MSCs (Fig. 9 F-H).  The BDNF-MSC treated eyes were found to have outer nuclear, 
outer plexiform, inner nuclear, and inner plexiform layers that were significantly 
thicker than GFP-MSC treated eyes (Fig. 9 A-D, p < 0.05).  In addition, the total 
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thickness of the retina was significantly greater in BDNF-MSC treated eyes, as 
compared to GFP-MSC treated eyes (Fig. 9 E).  
In order to examine the integrity of retinal architecture more closely, we 
stained the neural retina with antibodies specific for antigens found in distinct retinal 
layers.  We have examined anti-recoverin-IR that labels photoreceptors in the outer 
nuclear layer (ONL) and bipolar cells in the inner nuclear layer (INL), and 
demonstrated more recoverin immunoreactivity in BDNF-MSC treated eyes as 
compared to GFP-MSC treated eyes (Fig. 10 A-C).  Anti-protien-kinase C α (PKCα), 
which labels rod bipolar cells, was used to assess the integrity of the INL.  We have 
shown in control and BDNF-MSC treated eyes that PKCα-IR bipolar cells are long 
radial cells (Fig. 10 D, E).  However, in GFP-MSC treated eyes, PKCα-IR bipolar 
cells are significantly smaller cells with stunted, misdirected processes (Fig. 10 F).  
An anti-syntaxin antibody was used to demonstrate the preservation of the inner 
plexiform layer (IPL).  Robust anti-syntaxin-IR was observed thoroughout the IPL in 
fellow and BDNF-MSC treated eyes, while the IPL of MSC-GFP treated eyes was 
significantly reduced (Fig. 10 G-I), as evidenced by syntaxin-IR.  Finally, Müller glia 
were labeled with anti-vimentin and anti-GFAP antibodies.  Anti-vimentin was used 
to examine the total retinal integrity, as it labels Müller glia running from the inner 
limiting membrane of the inner retina to the outer limiting membrane.  Consistent 
with morphometric analysis, we have observed longer vimentin-IR Müller glia in 
control and BDNF-MSC treated eyes, and considerably smaller Müller glia in GFP-
MSC treated eyes (Fig 10 J-L).  An anti-GFAP antibody was used to determine if 
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Müller glia were reactive.  In control eyes, GFAP only labeled astrocytes in the optic 
fiber layer, vitreal to the GCL (Fig. 10 M).  However, significant GFAP-IR was 
observed in Müller glia in BDNF-MSC and GFP-MSC treated eyes, which is 
consistent with increased IOP in those eyes (Fig. 10 N, O).  Taken together, these 
results demonstrate a significant neuroprotection of retinal architecture in BDNF-
MSC treated eyes.   
Discussion 
 In the experiments presented here we have demonstrated that MSCs are 
useful vehicles to deliver neuroprotective substances to diseased retinas.  We have 
shown that MSCs are readily transformed using lentiviral vectors to secrete the 
neurotrophin BDNF, which we subsequently verified as being bioactive, as 
evidenced using cultures of rat DRGs.  We have demonstrated that BDNF released 
from engineered MSCs is able to protect visual function, as assessed using ERGs 
and computerized pupillometry.  The functional preservation observed in 
hypertensive eyes treated with BDNF-MSCs, but not GFP-MSCs, correlated with 
increased anatomical preservation.   The anatomical preservation observed included 
RGCs, their axons in the optic nerve, and other retinal neurons.  These results 
represent an advance in neuroprotection of glaucomatous retinas using stem cell-
mediated therapies.   
 The results presented here are consistent with previous work that 
demonstrated bolus injection, or viral mediated transfer of BDNF to the retina was 
able to preserve retinal architecture64, 66, 67, 69, 70.  We believe that MSCs are ideal 
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vehicles to deliver neuroprotective substances to glaucomatous retinas, as they are 
capable of surviving at least 6 weeks in eyes with dramatically increased IOP.  This 
suggests that MSCs could potentially be used in a clinical setting as a minimally 
invasive treatment for glaucoma, that is capable of delivering neuroprotective 
substances to the retina.  Aside from the abiity to survive for prolonged periods of 
time in hypertensive retinas, MSCs are attractive for other reasons.  MSCs have the 
potential to be used for autologous transplants, which would help to alleviate 
concerns associated with rejection of transplanted cells, as well as transmission of 
diseases between donors and recipients.  Additionally MSCs do not have any moral 
or ethical concerns associated with using them.  We will continue to evaluate the use 
of MSCs as vehicles to deliver neuroprotective substances to glaucomatous retinas 
using large animal models. 
 Supplying BDNF to hypertensive retinas in rats was logical, as a severe 
decrease in retrograde BDNF transport is observed in this rodent model of 
glaucoma3, 4.  While we have shown robust protection of visual function with BDNF, 
other factors such as CNTF and GDNF have been shown to attenuate cell loss in 
models of retinal disease30, 75-78.  We will examine the ability of these molecules to 
preserve retinal architecture and function in rodent and large animal models of 
glaucoma using MSCs as bio-factories to produce them.  We are aware that species 
variations may exist, so it is essential to examine normal and glaucomatous eyes in 
large animal models to look for modulation of pro-survival molecules and their 
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receptors at the genetic and protein level.  This will ensure that appropriate factors 
are examined.   
 Taken together, our results are the first exciting step toward development of 
cell-based strategies to preserve retinal architecture and function in glaucomatous 
optic neuropathies.  
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Figure Legends 
Table 1. Antibodies used in this study.  
Table 2.  Ratio analysis of ERG responses. Parameters with a significant difference 
are in bold text. 
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Table 3.  Quantification of retinal layer thickness (µm).  Abbreviations: outer nuclear 
layer (ONL), outer plexiform layer (OPL), inner nuclear layer (INL), inner plexiform 
layer (IPL).   
Figure 1. MSCs can be engineered with lentiviral vectors.  MSCs infected with 
lentiviral BDNF vectors (A-C) showed increased expression of BDNF (A, Arrows).  
Anti-GFP antibody staining (B) indicates GFP can be used to detect engineered 
MSCs.  Merged image (C) demonstrates perinucler localization of BDNF-IR in 
BDNF-MSCs (arrows).  Control MSCs infected with lentiviral GFP vectors (D-F) 
show diffuse BDNF immunoreactivity throughout the cell (D, arrows).  Robust GFP 
expression is apparent using conventional fluorescence microscopy (E).  Merged 
image (F) demonstrates the BDNF localization in GFP-MSCs.  Scale bar: 100 µm for 
all images in F. 
Figure 2. MSCs secrete bioactive BDNF.  ELISA analysis revealed BDNF-MSCs 
secrete 41.40 ± 1.32 ng BDNF/ 106 cells/ day, a significant increase over control 
GFP-MSCs secreting 0.97 ± 0.52 ng BDNF/ 106 cells/ day (A).  Media conditioned by 
BDNF-MSCs or GFP-MSCs was collected and applied to E17 rat dorsal root ganglia 
(DRG) explant cultures to assay and quantitate BDNF bioactivity (B).  DRGs were 
treated with MSC growth media (C), media conditioned by GFP-MSCs (D), BDNF-
MSCs (E), or MSC growth media supplemented with 50 ng rhBDNF (F).   Montage 
images of DRGs were collected, and subsequently scored by naïve observers (B).  
No significant difference was observed in the modest outgrowth of neurites induced 
by MSC media only (C) or GFP-MSC conditioned media (B, D, p > 0.05).  BDNF-
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MSC conditioned media induced robust outgrowth of neurites from DRGs (E), and 
did not differ significantly from DRG outgrowth induced by rhBDNF supplemented 
media (B, F, p > 0.05).  Each group of DRGs exposed to BDNF, however, had 
significantly more neurite outgrowth compared to each of the control groups (p < 
0.05).  Scale bar : 400 µm in F for C, D, E, F.  
Figure 3.  Chronic ocular hypertension results in increased IOP.  No difference was 
observed in baseline measurements of IOP between BDNF-MSC or GFP-MSC 
treated eyes and their fellow eyes prior to induction of COH (A).  There was, 
however, significant increases in IOP at 10 and 25 days post-op (A, p < 0.05).  The 
IOP for each group decreased by 42 days post-op, and was not significantly greater 
than the IOP for fellow eyes (A, p > 0.05).  The difference in IOP between 
experimental and fellow eyes was calculated, which showed no significant relative 
difference between groups.  This statistical analysis revealed no difference in the 
ΔIOP between BDNF-MSC and GFP-MSC groups at each timepoint examined (B). 
Figure 4.  Transplant of BDNF-MSCs preserved retinal function in COH eyes.  ERG 
amplitudes of BDNF-MSC injected retinas were significantly larger than GFP-MSC 
treated retinas 40 days after transplant.  Maximum combined responses for control 
retinas for each group did not differ significantly from each other (A, a-wave 179.1 ± 
28.46 µV, b-wave 307.5 ± 42.83 µV p>0.05, unpaired t-test).  Responses from 
BDNF-MSC treated eyes (B, a-wave 48.90 ± 13.80 µV, b-wave 106.2 ± 27.91µV) 
were significantly greater than those from GFP-MSC treated eyes (C, a-wave 19.24 
± 8.50 µV, b-wave 38.49 ± 25.08 µV, p < 0.05, unpaired t-test).  Oscillatory potential 
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sum of peaks for control eyes in each group did not differ (D, 144.9 ± 21.82 µV, p > 
0.05, unpaired t-test).  Again, BDNF-MSCs (E, 48.59 ± 16.31 µV), showed greater 
responses than GFP-MSC treated eyes (F, 15.10 ± 6.06 µV, p < 0.05, unpaired t-
test).  Finally, flicker responses (20 Hz) for control eyes (G, 16.25 ± 1.93 µV) did not 
vary significantly, while the responses from BDNF-MSC treated eyes (H, 6.11 ± 2.03 
µV) were significantly larger than GFP-MSC treated eyes (I, 1.15 ± 0.42 µV, p < 
0.05, unpaired t-test). 
Figure 5.  Computerized pupillometry analysis of the pupil light response at 42 days 
post transplant.  Ratios of indirect/ direct responses of control right eyes are 
presented for change in pupil area (A), change in pupil diameter (B), change in pupil 
constriction velocity (C), change in pupil constriction latency (D), change in pipil 
dilation velocity (E) and change in pupil dilation latency (F).   
Figure 6. MSCs can survive following transplant into hypertensive eyes.  
Transduced MSCs were detected in the retina using an anti-GFP antibody at the 
termination of the experiment (A, D).  MSCs were detected adjacent to the GCL in 
animals with retinas that were primarily intact (B, C).  In addition, MSCs were found 
to be integrated into the retinas of animals with severe degeneration (E, F).  Scale 
bar : 50 µm for all images in F.     
Figure 7: BDNF-MSC transplanted cells serve to protect Brn3a-IR RGCs in COH 
eyes.  Cryosectioned retinas were immuno-stained with anti-Brn3a antibody to label 
RGCs in control and experimental eyes.  Untreated control eyes for each group were 
found to have 355.4 ± 31.20 (BDNF) and 362.9 ± 36.47 (GFP) Brn3a-
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immunoreactive (IR) cells per section (A, B representative example).  BDNF-MSC 
treated COH eyes (C, D) had significantly less Brn3a-IR cells per section than 
untreated fellow eyes (G, 175.1 ± 28.16, p<0.05).  GFP-MSC treated COH eyes also 
had significantly fewer Brn3a-IR cells per section than untreated fellow eyes (G, 74.0 
± 21.53, p<0.01).  Analysis of BDNF-MSC and GFP-MSC treated eyes revealed 
significantly more Brn3a-IR cells per section in BDNF-MSC eyes when compared 
with the GFP-MSC treated COH eyes (G, p < 0.05).   
Figure 8:  BDNF-MSC transplants preserve optic nerve integrity.  Blind observers 
scored each optic nerve for the extent of degeneration present and optic nerve 
integrity.  Optic nerves with greater degeneration received higher scores (scale 1 – 
5).  No significant difference was observed between the optic nerves from COH eyes 
treated with BDNF-MSCs (A, 2.4 ± 0.40) and the fellow optic nerves (B, 1.4 ± 0.25, p 
> 0.05, unpaired t-test).  A significant difference was observed between optic nerves 
from COH eyes treated with GFP-MSCs (C, 3.6 ± 0.75), and control optic nerves 
from fellow, untreated eyes (D, 1.0, p < 0.05, unpaired t-test). 
Figure 9.  BDNF-MSC transplants preserve retinal architecture.  Images were taken 
of each retina, and the thickness of each layer of the retina was quantified for 
experimental and control eyes in each group.  Statistical analysis revealed no 
significant difference between BDNF-MSC treated eyes with their fellow control right 
eyes for any retinal layer.  GFP-MSC retinal layers, on average, were significantly 
thinner than controls.  Comparison of BDNF-MSC and GFP-MSC treated eyes 
revealed thicker retinal layers in BDNF-MSC eyes in the outer nuclear layer (A), 
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outer plexiform layer (B), inner nuclear layer (C), inner plexiform layer (D), as well as 
total retinal thickness (E).  Representative images for control, fellow eye (F), BDNF-
MSC treated eye (G), and GFP-MSC treated eye (H).  Scale bar : 50 µm for images 
F, G, H.   
Figure 10.  Phenotypic analysis of retinal structure.  Anti-recoverin-IR demonstrated 
similar levels of photoreceptors in fellow and BDNF-MSC treated eyes, and a 
decreased level of recoverin-IR photoreceptors in GFP-MSC treated eyes (Fig. 10 A-
C).  Inner retinal analysis revealed PKC-α-IR bipolar cells in control and BDNF-MSC 
treated eyes had similar morphologies, while PKC-α-IR bipolar cells in GFP-MSC 
retinas had deformed morphologies (D-F).  Analysis of IPL integrity with anti-syntaxin 
demonstrates significantly thicker IPLs in fellow and BDNF-MSC treated animals as 
compared to GFP-MSC treated animals (G-I).  Vimentin-IR was used to examine 
retinal integrity.  We have shown that fellow and BDNF-MSC treated eyes have 
significantly larger Müller glia, as compared to GFP-MSC treated eyes.  Finally, the 
activation of Müller glia was assessed using anti-GFAP-IR.  We have determined 
that control, fellow retinas only displayed GFAP in the astrocytes adjacent to the 
GCL, while BDNF-MSC and GFP-MSC treated eyes had reactive Müller glia 
expressing GFAP, consistent with hypertensive eyes (M-O).  Scale bar in O: 50 µm 
for all images.   
Supplemental Table 1. Intraocular pressures of each eye and ΔIOP for each group 
Pre-rec and, 10, 25, and 42 days post-op (PO).  Results presented in bold are 
significantly different as compared to fellow eyes (dIOP = ΔIOP).   
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Supplemental Table 2.  ERG amplitudes of hypertensive and control eyes at 20 
and 40 days post op. Parameters with a significant difference are in bold text. 
Supplemental Table 3.  Latencies of ERG responses of hypertensive and control 
eyes at 20 and 40 days post-op. Parameters with a significant difference are in bold 
text. 
Supplemental Figure 1.  Representative ERG traces from a BDNF-MSC treated 
eye and fellow eye 20 days post-op.  Representative traces of scotopic rod (A, B), 
scotopic maximum combined response (C, D), photopic cone (E, F), oscillatory 
potentials (G, H), and photopic flicker (I, J) responses for BDNF-MSC treated eye (A, 
C, E, G, I), and the fellow eye (B, D, F, H, J).  Scale bar in B for A, B, C, D.  Scale 
bar in F for E, F.  Scale bar in H for G, H.  Scale bar in J for I, J.   
Supplemental Figure 2.  Representative ERG traces from a GFP-MSC treated eye 
and fellow eye 20 days post-op.  Representative traces of scotopic rod (A, B), 
scotopic maximum combined response (C, D), photopic cone (E, F), oscillatory 
potentials (G, H), and photopic flicker (I, J) responses for the GFP-MSC treated eye 
(A, C, E, G, I), and the fellow eye (B, D, F, H, J).  Scale bar in B for A, B, C, D.  Scale 
bar in F for E, F.  Scale bar in H for G, H.  Scale bar in J for I, J.   
Supplemental Figure 3.  Representative ERG traces from a BDNF-MSC treated 
eye and fellows 40 days post-op.  Representative traces of scotopic rod (A, B), 
scotopic maximum combined response (C, D), photopic cone (E, F), oscillatory 
potentials (G, H), and photopic flicker (I, J) responses for a BDNF-MSC treated eye 
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(A, C, E, G, I), and the fellow eye (B, D, F, H, J).  Scale bar in B for A, B, C, D.  Scale 
bar in F for E, F.  Scale bar in H for G, H.  Scale bar in J for I, J.   
Supplemental Figure 4.  Representative ERG traces from GFP-MSC treated eyes 
and fellows 40 days post-op.  Representative traces of scotopic rod (A, B), scotopic 
maximum combined response (C, D), photopic cone (E, F), oscillatory potentials (G, 
H), and photopic flicker (I, J) responses for GFP-MSC treated eyes (A, C, E, G, I), 
and the fellow eye (B, D, F, H, J).  Scale bar in B for A, B, C, D.  Scale bar in F for E, 
F.  Scale bar in H for G, H.  Scale bar in J for I, J.   
Supplemental Figure 5.  MSCs can survive following transplantation into 
hypertensive eyes.  MSCs were found in many areas of the eye including the 
vitreous (A-C), near the optic nerve head (D-F), and at the retinal periphery (G-I).  
Scale bar : 50 µm for all images in I.    
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Antibody Antigen Cell Type Dilution Source 
Anti-
Recoverin 
Recoverin Rod and Cone 
Photoreceptors 
1:750 A.M. Dizoor 
Anti-PKC α Protein 
kinase C α 
Rod bipolar 
cells 
1:100 Santa Cruz 
Anti-Vimentin Vimentin Müller glia and 
astrocytes 
1:200 Dako 
Anti-GFAP Glial 
fibrillary 
acidic 
protein 
Astrocytes and 
reactive Müller 
glia 
1:250 ICN 
Anti-HPC-1 Syntaxin Amacrine cells, 
Ganglion Cells 
1:150 Chemicon 
International 
Anti-Brn3a Brn3a 
Transcriptio
n Factor 
Ganglion Cells 1:100 Santa Cruz 
Anti-GFP Green 
Fluorescent 
Protein 
GFP Expressing 
rMSCs 
1:75 Chemicon 
International 
Table 1 
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20 Days Post-Op Amplitude Ratio (Exp. Eye / Fellow) * 100 
Parameter BDNF-MSC GFP-MSC Significance P-Value 
Max Combined A Wave 22.14 ± 4.45 5.15 ± 2.68 * 0.0125 
Max Combined B Wave 34.28 ± 5.01 11.91 ± 5.53 * 0.015 
Rod A Wave  
55.14 ± 
13.31 
53.29 ± 
29.37 ns 0.9481 
Rod B Wave 28.55 ± 6.86 7.39 ± 3.88 * 0.0377 
Cone A Wave 131± 38.73 
63.45 ± 
23.94 ns 0.1653 
Cone B Wave 
65.52 ± 
11.33 26.49 ± 6.09 * 0.0162 
Oscilatory Potentials (Sum of 
Peaks) 17.36 ± 2.07 10.53 ± 3.17 ns 0.0769 
Flicker (20 Hz) 21.82 ± 4.31 10.97 ± 3.31 ns 0.0863 
Flicker (P1-N3 Amplitude) 31.09 ± 4.1 28.79 ± 6.73 ns 0.7683 
     
40 Days Post-Op Amplitude Ratio (Exp. Eye / Fellow) * 100 
Parameter BDNF-MSC GFP-MSC Significance P-Value 
Max Combined A Wave 23.35 ± 5.15 10.08 ± 6.28 * 0.0214 
Max Combined B Wave 33.80 ± 7.19 
14.06 ± 
12.67 * 0.0143 
Rod A Wave  
91.07 ± 
10.09 
40.61 ± 
18.48 * 0.031 
Rod B Wave 31.56 ± 6.98 13.03 ± 9.46 * 0.0205 
Cone A Wave 130 ± 44  104 ± 46 ns 0.5748 
Cone B Wave 29.54 ± 7.32 14.40 ± 7.75 ns 0.0962 
Oscilatory Potentials (Sum of 
Peaks) 
42.53 ± 
15.42 13.46 ± 7.96 * 0.0438 
Flicker (20 Hz) 
28.52 ± 
10.43 3.52 ± 0.07 * 0.0102 
Flicker (P1-N3 Amplitude) 29.11 ± 8.58 16.41 ± 5.0 ns 0.2578 
Table 2 
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Layer BDNF-MSC BDNF-Fellow 
ONL (µm) 35.74 ± 3.21 41.65 ± 1.53 
OPL (µm) 6.72 ± 0.45 8.72 ± 0.28 
INL (µm) 15.08 ± 1.61 19.84 ± 2.53 
IPL (µm) 41.25 ± 7.50 45.95 ± 8.04 
Total (µm) 137.5 ± 12.01 170.4 ± 9.52 
   
 GFP-MSC GFP-Fellow 
ONL (µm) 22.11 ± 4.69 45.58 ± 2.44 
OPL (µm) 4.95 ± 0.46 10.83 ± 1.06 
INL (µm) 10.07 ± 2.28 22.74 ± 3.62 
IPL (µm) 14.72 ± 5.86 46.13 ± 11.47 
Total (µm) 67.80 ± 18.49 174.8 ± 17.82 
Table 3 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
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Figure 8 
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Figure 9 
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Figure 10 
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 BDNF-MSC Fellow GFP-MSC Fellow 
Pre-Rec (mmHg) 15.86 + 0.77 15.29 + 0.92 14.33 + 0.84 14.17 + 0.98 
10 Day PO (mmHg) 21.36 - 1.34 11.79 - 0.73 20.83 + 1.19 12.33 + 0.81 
25 Day PO (mmHg) 18.14 + 0.79 12.86 + 0.70 19.58 + 1.8 13.33 + 0.71 
42 Day PO (mmHg) 15.17 + 1.0 12.83 + 0.47 14.75 + 0.83 12.42 + 0.61 
     
 BDNF Δ IOP GFP Δ IOP p-value  
Pre-Rec (mmHg) 0.57 + .48 0.16 + 0.74 0.84  
10 Day PO (mmHg) 9.57 + 0.82 8.5 + 0.93 0.36  
25 Day PO (mmHg) 5.28 + 0.52 6.25 + 1.7 0.83  
42 Day PO (mmHg) 2.33 + 1.05 2.33 + 1.0 0.86  
Supplemental Table 1 
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20 Day Post-Op Amplitudes (µV) Experimental Eye 
Parameter BDNF-MSC GFP-MSC Sig. P-Value 
Max Combined A Wave 20.97 ±  6.561 3.206 ±  1.185 * 0.0304 
Max Combined B Wave 47.71 ±  10.51 19.02 ±  7.134 *  0.0186 
Rod A Wave  2.499 ± 0.5242 3.982 ±  0.8921 ns 0.2169 
Rod B Wave 17.52 ±  4.918 5.024 ±  2.159 * 0.046 
Cone A Wave 3.223 ±  .9039 2.494 ±  0.5823 ns 0.9901 
Cone B Wave 16.99 ±  1.818 8.050 ±  1.547 ** 0.0054 
Oscilatory Potentials  13.34 ± 3.564 9.278 ±  2.546 ns 0.3693 
Flicker (20 Hz) 1.909 ±  .7340 1.070 ±  .3824 ns 0.5041 
Flicker (P1-N3 Amplitude) 6.329 ±  1.247 6.438 ± 0.8900 ns 0.7408 
     
20 Day Post-Op Amplitudes (µV) Fellow Eye 
Parameter BDNF-Fellow GFP-Fellow Sig. P-Value 
Max Combined A Wave 76.28 ± 12.22 76.36 ± 18.89 ns 0.9372 
Max Combined B Wave 162.4 ± 24.68 174.4 ± 40.61 ns 0.9269 
Rod A Wave  4.59 ± 0.94 4.31 ± 1.43 ns 0.8497 
Rod B Wave 75.09 ± 7.90 84.52 ± 22.12 ns 0.9845 
Cone A Wave 3.46 ± 1.05 5.304 ± 1.617 ns 0.3677 
Cone B Wave 34.26 ± 4.08 29.08 ± 9.11 ns 0.3211 
Oscilatory Potentials  79.86 ± 11.94 84.59 ± 16.62 ns 0.8987 
Flicker (20 Hz) 8.94 ± 1.68 10.98 ± 3.00 ns 0.6074 
Flicker (P1-N3 Amplitude) 21.83 ± 3.68 22.02 ± 5.22 ns 0.9894 
     
40 Day Post-Op Amplitudes (µV) Experimental Eye 
Parameter BDNF-MSC GFP-MSC Sig. P-Value 
Max Combined A Wave 48.90 ± 13.80 19.24 ± 8.50 * 0.0433 
Max Combined B Wave 106.2 ± 27.91 38.49 ± 25.08 * 0.0236 
Rod A Wave  7.31 ± 0.76 3.71 ± 1.55 * 0.0419 
Rod B Wave 48.33 ± 11.74 4.22 ± 1.35 *** 0.0002 
Cone A Wave 4.16 ± 0.68 7.37 ± 2.16 ns 0.4763 
Cone B Wave 10.62 ± 3.54 10.48 ± 3.54 ns 0.9818 
Oscilatory Potentials 48.59 ± 16.31 15.10 ± 6.06 * 0.0453 
Flicker (20 Hz) 6.11 ± 2.03 1.15 ± 0.42 * 0.0212 
Flicker (P1-N3 Amplitude) 9.02 ± 2.91 6.25 ± 1.59 ns 0.5256 
     
40 Day Post-Op Amplitudes (µV) Fellow Eye 
Parameter BDNF-Fellow GFP-Fellow Sig. P-Value 
Max Combined A Wave 179.1 ± 28.46 155.8 ± 24.45 ns 0.4224 
Max Combined B Wave 307.5 ± 42.83 270.9 ± 35.79 ns 0.4867 
Rod A Wave  8.23 ± 0.81 8.93 ± 3.28 ns 0.5338 
Rod B Wave 142.6 ± 20.83 147.2 ± 21.13 ns 0.9157 
Cone A Wave 6.118 ±  2.396 7.075 ± 1.996 ns 0.6376 
Cone B Wave 52.47 ± 6.76 51.18 ± 8.162 ns 0.834 
Oscilatory Potentials  137.9 ± 19.19 144.9 ± 21.82 ns 0.8518 
Flicker (20 Hz) 18.43 ± 2.26 16.25 ± 1.93 ns 0.5529 
Flicker (P1-N3 Amplitude) 44.38 ± 4.95 42.65 ± 2.93 ns 0.922 
Supplemental Table 2 
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20 Day Post-Op Latency (ms) Experimental Eye  
Parameter BDNF-MSC GFP-MSC Significance P-Value 
Max Combined A Wave 21.29 ±  2.24 20.50 ± 3.53 ns 0.6984 
Max Combined B Wave 46.14 ±  5.54 41.50 ± 4.58 ns 0.5313 
Rod A Wave  26.5 ± 3.57 17.5 ± 3.84 ns 0.0964 
Rod B Wave 66.17 ± 10.90 42 ± 5.75 ns 0.1295 
Cone A Wave 17.71 ± 2.20 24.33 ± 4.94 ns 0.3195 
Cone B Wave 49.14 ± 5.77 47 ± 7.74 ns 0.7266 
Flicker (N1-P1 Latency) 37.14 ± 4.34 38.88 ± 5.93 ns 0.917 
     
20 Day Post-Op Latency (ms) Fellow Eye  
Parameter BDNF-Fellow GFP-Fellow Significance P-Value 
Max Combined A Wave 13.29 ± 0.29 15.50 ± 1.15 ns 0.0609 
Max Combined B Wave 32.29 ± 0.71 31.50 ± 0.72 ns 0.4451 
Rod A Wave  29.33 ± 0.80 23.80 ± 2.71 ns 0.085 
Rod B Wave 57.71 ± 4.19 57.50 ± 4.46 ns 0.9747 
Cone A Wave 17.86 ± 0.70 16.83 ± 2.19 ns 0.4634 
Cone B Wave 43.29 ± 1.10 39.17 ± 3.03 ns 0.2026 
Flicker (N1-P1 Latency) 36.27 ± 3.67 39.12 ± 1.05 ns 0.4072 
     
40 Day Post-Op Latency (ms) Experimental Eye  
Parameter BDNF-MSC GFP-MSC Significance P-Value 
Max Combined A Wave 25 ± 1.41 21.25 ± 2.02 ns 0.1672 
Max Combined B Wave 38.17 ± 1.70 38 ± 4.0 ns 0.7857 
Rod A Wave  26.13 ± 2.42 20.83 ± 3.54 ns 0.1917 
Rod B Wave 71 ± 4.17 45.67 ± 3.79 ** 0.0014 
Cone A Wave 14.33 ± 2.404 17.57 ± 3.176 ns 0.4505 
Cone B Wave 39.50 ± 3.29 35.14 ± 4.67 ns 0.414 
Flicker (N1-P1 Latency) 34.80 ± 2.38 30.50 ± 6.05 ns 0.3637 
     
40 Day Post-Op Latency (ms) Fellow Eye  
Parameter BDNF-Fellow GFP-Fellow Significance P-Value 
Max Combined A Wave 13.83 ± 0.40 13.25 ± 0.16 ns 0.1686 
Max Combined B Wave 32.33 ± 1.17 31.25 ± 0.31 ns  0.3405 
Rod A Wave  24.50 ± 2.29 22.67 ± 2.43 ns 0.6617 
Rod B Wave 58.38 ± 4.65 50.50 ± 0.96 ns 0.1463 
Cone A Wave 15.33 ± 1.63 13.14 ± 0.70 ns 0.26 
Cone B Wave 44.0 ± 1.0 45.71 ± 0.80 ns 0.2064 
Flicker (N1-P1 Latency) 41.48 ± 0.35 39.65 ± 0.81 ns 0.0648 
Supplemental Table 3 
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Supplemental Figure 1 
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Supplemental Figure 2 
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Supplemental Figure 3 
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Supplemental Figure 4 
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Supplemental Figure 5 
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CHAPTER 4: GENERAL CONCLUSIONS 
The studies presented in this dissertation are the first to describe robust 
neuroprotection of retinal architecture and function using stem cell-based therapies 
in rodent models of glaucoma.  This robust neuroprotection was accomplished using 
BDNF released from mesenchymal stem cells using in vitro and in vivo models of 
glaucoma.  These proof-of-principle studies make it clear that using mesenchymal 
stem cells as biofactories to prevent degeneration in glaucomatous retinas is a 
useful strategy.  Furthermore, we believe that this strategy has the potential to be 
used for treatment of human glaucoma, and has the ability to work synergistically 
with currently available therapies.  
 
We have made a number of very important observations in these studies, including: 
 
1. Mesenchymal stem cells can be engineered to produce and secrete bioactive 
Brain-derived neurotrophic factor, as evidenced using multiple assays. 
2. The RGC-5 cell line is a useful model of retinal ganglion cells, in vitro, 
following differentiation with staurosporine.  After SS-differentiation, RGC-5s 
cease cell division, and express neuronal-associated proteins consistent with 
mature retinal ganglion cells.   
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3. We have demonstrated that SS-differentiated RGC-5s were susceptible to the 
cellular stressors hydrogen peroxide and glutamate, as evidenced by 
significant RGC-5 cell loss following exposure to these stressors.   
4. We subsequently demonstrated that BDNF-MSCs, but not GFP-MSCs, were 
able to attenuate this cell loss.  This result was verified by application of 
purified rhBDNF.       
5. We have shown that MSCs are able to survive in hypertensive retinas for up 
to 6 weeks following transplant in an in vivo model of glaucoma. 
6. We have shown BDNF-MSCs were able to preserve retinal architecture in a 
rat model of glaucoma.  This was demonstrated by the presence of 
significantly more retinal ganglion cells, their axons in the optic nerve, and 
other retinal neurons as assessed using retinal layer analysis in BDNF-MSC 
treated animals, as compared to GFP-MSC treated animals.  
7. We have demonstrated a significant preservation of retinal function in BDNF-
MSC treated hypertensive eyes compared to GFP-MSC treated eyes, as 
assessed using electroretinography and computerized pupillometry.   
 
The final conclusion of this dissertation is that mesenchymal stem cells are 
useful vehicles for the delivery of neuroprotective proteins to animal models 
of glaucoma, and have the potential to be used as a clinical treatment.   
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RECCOMENDATIONS FOR FUTURE RESEARCH 
 The results presented in this dissertation represent an excellent starting-point 
for analyzing mesenchymal stem cells as potential vehicles to serve for treatment of 
human optic neuropathies.   
 Additional experiments to be performed in rats include the analysis of other 
potentially neuroprotective proteins, or combinations of proteins.  Proteins that would 
be most interesting to examine include GDNF, NT3, NT4, and CNTF.  Additionally, it 
should be determined if there is a critical period for addition of these proteins to the 
neural retina which results in preservation of retinal function.  While we know that 
BDNF secreted from MSCs preserves retinal architecture and function, we do not 
know which cells it is binding to or what specific intracellular cascades BDNF is 
eliciting in COH rat retinas.  Devising experiments to examine these questions is 
essential to understanding the molecular basis of neuroprotection.   
The next step in these series of experiments would be to analyze the efficacy 
of MSC delivery of neuroprotective proteins to large animal models of glaucoma, 
particularly canines.  Canine eyes would be an intermediate between rats and 
humans, and represent models that are very similar to human eyes in size and 
anatomy.  Additionally, genetic models for glaucoma are available in canines, 
allowing researchers to examine the effectiveness of transplanted MSCs in 
preserving retinal function and architecture at all stages of the disease.  Finally, 
these genetic models allow researchers to examine potential neuroprotection over 
months and years, as opposed to several weeks in rats.     
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 Prior to transplantation of neuroprotective protein secreting MSCs into 
canine eyes, a thorough immunohistochemical and genetic analysis of neurotrophins 
and their receptors should be completed in normal and glaucomatous eyes.  This 
analysis will allow the researchers to identify proteins that have the potential to 
provide neuroprotection to canine eyes, and to determine what variation is present 
between dogs and rats.  Lessons learned from this analysis will help to guide 
potential human clinical trials, as screens of glaucomatous and normal human tissue 
can also be performed.   
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